<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000501.pub4" GROUP_ID="NEONATAL" ID="815999102110420182" MERGED_FROM="" MODIFIED="2016-08-22 15:35:07 +0100" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Short title (no longer in use): Vitamin A supplementation in VLBW infants&lt;/p&gt;&lt;p&gt;Do not remove&lt;br&gt;CL 4/02&lt;/p&gt;&lt;p&gt;sent to Loni for update Dec 5/06&lt;/p&gt;&lt;p&gt;sent to Darlow March 26-07&lt;br&gt;sent to Darlow for approval June 27-07&lt;br&gt;CL 4/07 (substantive update)&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-08-16 10:35:21 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-08-16 10:00:13 -0400" MODIFIED_BY="Colleen Ovelman">
<TITLE MODIFIED="2014-10-22 14:53:49 -0400" MODIFIED_BY="[Empty name]">Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants</TITLE>
<CONTACT>
<PERSON ID="4568" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Brian</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Darlow</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Paediatrics</POSITION>
<EMAIL_1>brian.darlow@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics</DEPARTMENT>
<ORGANISATION>University of Otago</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 3 3640 747</PHONE_1>
<PHONE_2>+64 3 3644 699</PHONE_2>
<FAX_1>+64 3 3644 907</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-08-16 10:00:13 -0400" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="4568" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Brian</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Darlow</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Paediatrics</POSITION>
<EMAIL_1>brian.darlow@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics</DEPARTMENT>
<ORGANISATION>University of Otago</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 3 3640 747</PHONE_1>
<PHONE_2>+64 3 3644 699</PHONE_2>
<FAX_1>+64 3 3644 907</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19709" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>P</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Graham</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>patrick.graham@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health and General Practice</DEPARTMENT>
<ORGANISATION>Christchurch School of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EEE82C9782E26AA20126CDD1B6925085" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Maria Ximena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rojas-Reyes</LAST_NAME>
<SUFFIX>RN. MSc.Ph.D</SUFFIX>
<POSITION>Clinical Epidemiologist, Associate Professor in Clinical Epidemiology</POSITION>
<EMAIL_1>mxrojas@gmail.com</EMAIL_1>
<EMAIL_2>mxrojas@javeriana.edu.co</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1>Cr. 7 #40-62, 2nd floor</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bogotá</CITY>
<ZIP/>
<REGION>DC</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+57 1 320 8320 ext 2811</PHONE_1>
<PHONE_2>+57 1 320 8320 ext 2799</PHONE_2>
<FAX_1>+57 1 285 6981</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-07-11 12:04:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New studies found and included or excluded: 27/05/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 27/05/07&lt;/p&gt;&lt;p&gt;Reformatted: 21/10/99&lt;/p&gt;" NOTES_MODIFIED="2016-07-11 12:04:35 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="5" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="5" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="5" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-08-02 10:44:37 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-11 12:04:42 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-08-02 10:44:37 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>This updates the review 'Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birth weight infants' published in the <I>Cochrane Database of Systematic Reviews</I> (<LINK REF="REF-Darlow-2011" TYPE="REFERENCE">Darlow 2011</LINK>).</P>
<P>Search updated May 2016. Two new trials were identified (<LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>).</P>
<P>Additional outcome of 'ROP requiring treatment' added post hoc.</P>
<P>Summary of findings table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-09-12 13:07:59 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-09-12 13:06:37 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>Additional secondary outcomes added. The methods have been updated to include the new risk of bias assessment and 'Summary of findings' tables. The risk of bias assessment has been completed for each trial and 'Summary of findings' tables added to the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-12 13:07:59 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>This updates the review "Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants" published in the <I>Cochrane Database of Systematic Reviews</I> (<LINK REF="REF-Darlow-2007" TYPE="REFERENCE">Darlow 2007</LINK>).</P>
<P>Search updated August 2011. No new trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-21 03:59:57 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-07-21 04:01:40 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>This review updates the existing review "Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants", published in the Cochrane Database of Systematic Reviews in 2002, Issue 2 (<LINK REF="REF-Darlow-2002" TYPE="REFERENCE">Darlow 2002</LINK>).</P>
<P>One further small trial has been identified and data from this trial added to the pooled data for the meta-analysis. There are now data on the neurodevelopmental status at 18 to 22 months postmenstrual age for infants included in the largest vitamin A supplementation trial, and this information has been included in this review. In addition, data from one trial that compared three different intramuscular vitamin A dosing regimens have been included.</P>
<P>The previous version of this review concluded that supplementing very low birthweight infants with vitamin A is associated with a reduction in oxygen requirement among survivors at 36 weeks postmenstrual age, as well as a reduction in death or oxygen requirement at one month of age. With data from the additional study, these conclusions remain the same. The information on follow-up at 18 to 22 months postmenstrual age from the largest included trial showed no evidence or benefit or harm from the intervention.</P>
<P>Based on biochemical data, the one study that investigated different intramuscular vitamin A dosing regimens suggested that the regimen used in the largest trial (5000 IU 3x weekly for four weeks) was optimal even though some infants still had poor vitamin A status.</P>
<P>The conclusion remains unchanged: clinicians must decide whether to utilise repeat intramuscular doses of vitamin A based upon the incidence of supplemental oxygen requirement at 36 weeks postmenstrual age in extremely low birthweight infants in their unit and their own assessment, based upon the review, of the benefits of a modest reduction in this outcome balanced against lack of other proven benefits and the acceptability of treatment. The follow-up data would support a decision either to treat or not to treat.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-07-21 04:00:01 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-10-22 15:24:16 -0400" MODIFIED_BY="Toby J Lasserson">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Christchurch School of Medicine, University of Otago</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-10-22 15:24:16 -0400" MODIFIED_BY="Toby J Lasserson">
<SOURCE MODIFIED="2010-12-21 11:28:59 -0500" MODIFIED_BY="Toby J Lasserson">
<NAME>WHO</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>A grant was provided by the WHO for an updated of this Cochrane Review.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-10-22 15:24:16 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-16 10:34:56 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-07-31 11:17:58 -0400" MODIFIED_BY="[Empty name]">Vitamin A supplementation to prevent deaths and short- and long-term illness in very low birth weight infants</TITLE>
<SUMMARY_BODY MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Review question:</B> Does supplementation with vitamin A prevent death, chronic lung injury and long-term neurodevelopmental disability in very low birth weight infants compared with a control (placebo or no supplementation)?</P>
<P>
<B>Background: </B>Vitamin A is a group of fat-soluble compounds used by the body for regulation and promotion of growth and differentiation of many cells, including cells in the retina of the eye and the cells that line the air passages in the lungs. Preterm infants have low vitamin A levels at birth. This may contribute to an increased risk of developing chronic lung disease and hence a requirement for oxygen. It is possible that an additional vitamin A supplement may reduce complications of prematurity, including abnormal development of the retina (retinopathy), bleeding in the brain (intraventricular haemorrhage), and damage to the gut from inflammation (necrotising enterocolitis) as well as reducing respiratory infections. Too much vitamin A is potentially harmful as it can raise intracranial pressure and cause skin and mucous membrane changes (injury or lesions), and vomiting.</P>
<P>
<B>Study characteristics:</B> Eleven trials were included in this review, ten comparing vitamin A with a control (placebo or no supplementation) and one comparing different vitamin A regimens. The search for eligible trials was updated in May 2016.</P>
<P>
<B>Results: </B>Compared to the control group, supplementing very low birth weight infants with vitamin A appears to have a small benefit in reducing the risk of death or oxygen requirement at one month of age and the risk of chronic lung disease (oxygen requirement) at 36 weeks' postmenstrual age (moderate-quality evidence). There was a marginal reduction of the combined outcome of death or chronic lung disease (moderate-quality evidence). Although there is a statistical reduction in chronic lung disease, these findings are consistent with either a meaningful impact on chronic lung disease or a negligible impact. The one trial that investigated neurodevelopmental status at 18 to 22 months of age correcting for prematurity found no evidence of benefit or harm associated with vitamin A supplementation compared to control (low-quality evidence). No adverse effects of vitamin A supplementation were reported, but it was noted that intramuscular injections of vitamin A were painful.</P>
<P>
<B>Conclusions: </B>Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in the outcome balanced against the lack of other proven benefits and the acceptability of the treatment. Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-08-16 10:34:06 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-10-13 13:17:05 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A is necessary for normal lung growth and the integrity of respiratory tract epithelial cells. Preterm infants have low vitamin A status at birth and this has been associated with an increased risk of developing chronic lung disease.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>To evaluate supplementation with vitamin A on the incidence of death or neonatal chronic lung disease and long-term neurodevelopmental disability in very low birth weight (VLBW) infants compared with a control (placebo or no supplementation), and to consider the effect of the supplementation route, dose, and timing.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>For the original review and subsequent updates, we searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>), MEDLINE, Science Citation Index, and the Oxford Database of Perinatal Trials. The reference lists of relevant trials, paediatric and nutrition journals, and conference abstracts and proceedings were handsearched up to 2010.</P>
<P>For the 2016 update, we used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 4), MEDLINE via PubMed (1 May 2016), EMBASE (1 May 2016), and CINAHL (1 May 2016). We also searched clinical trials' databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-12-02 10:55:19 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing vitamin A supplementation with a control (placebo or no supplementation) or other dosage regimens in VLBW infants (birth weight &#8804; 1500 grams or less than 32 weeks' gestation).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-08-16 10:34:06 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors screened the search results, extracted data, and assessed the trials for risk of bias. Results were reported as risk ratios (RR), risk differences (RD), and number needed to treat to benefit (NNTB), all with 95% confidence intervals (CI). Trialists were contacted for additional data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-08-16 10:15:53 -0400" MODIFIED_BY="[Empty name]">
<P>Eleven trials met the inclusion criteria. Ten trials (1460 infants) compared vitamin A supplementation with a control and one (120 infants) compared different regimens of vitamin A supplementation. Compared to the control group, vitamin A appeared to have a small benefit in reducing the risk of death or oxygen requirement at one month of age (typical RR 0.93, 95% CI 0.88 to 0.99; typical RD &#8722;0.05, 95% CI &#8722;0.10 to &#8722;0.01; NNTB 20, 95% CI 10 to 100; 6 studies, 1165 infants) and the risk of chronic lung disease (oxygen requirement) at 36 weeks' postmenstrual age (typical RR 0.87, 95% CI 0.77 to 0.99; typical RD &#8722;0.07, 95% CI &#8722;0.13 to &#8722;0.01; NNTB 11, 95% CI 6 to 100; 5 studies, 986 infants) (moderate-quality evidence). There was a marginal reduction of the combined outcome of death or chronic lung disease (typical RR 0.92, 95% CI 0.84 to 1.01; typical RD &#8722;0.05, 95% CI &#8722;0.11 to 0.01; 4 studies, 1089 infants). Neurodevelopmental assessment of 88% of the surviving infants in the largest trial showed no difference between the groups at 18 to 22 months of age, corrected for prematurity (low-quality evidence). There is no evidence to support different vitamin A dosing regimens. No adverse effects of vitamin A supplementation were reported, but it was noted that intramuscular injections of vitamin A were painful.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-14 05:21:15 -0500" MODIFIED_BY="[Empty name]">
<P>Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in the outcome balanced against the lack of other proven benefits and the acceptability of the treatment. Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-08-16 10:34:56 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A is the generic name for a group of fat-soluble compounds which have the biological activity of the primary alcohol retinol. Vitamin A is involved in the regulation and promotion of growth and differentiation of many cells and in maintaining the integrity of the epithelial cells of the respiratory tract. Vitamin A is also necessary for formation of the photosensitive visual pigment in the retina, reproductive functions, and immunocompetence. Carotenoids, dietary precursors of vitamin A, have antioxidant properties.</P>
<P>The foetus accumulates vitamin A in the third trimester. The transport mechanism of vitamin A across the placenta and its regulation are not fully established. Premature infants have reduced hepatic stores of retinyl ester. In the plasma, vitamin A is bound to a specific carrier protein, retinol-binding protein (RBP), and the resulting complex is further complexed with transthyretin (formerly pre-albumin) (<LINK REF="REF-Mactier-2005" TYPE="REFERENCE">Mactier 2005</LINK>). Premature infants have lower concentrations of plasma RBP than term infants, and most preterm infants have low plasma vitamin A concentrations and low plasma retinol/RBP molar ratios, suggesting they are vitamin A deficient (<LINK REF="REF-Shenai-1993" TYPE="REFERENCE">Shenai 1993</LINK>). Inadequate provision and delivery of vitamin A postnatally may exacerbate the problem.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>Preterm infants who are unable to tolerate oral feeds are routinely fed parenterally with both an amino acid and dextrose mixture and a lipid emulsion. Multivitamin preparations containing retinol or an equivalent are commonly added to the amino acid and dextrose mixture and infused over 24 to 48 hours, but significant losses in delivered vitamin A have been shown to result from light degradation and from adsorption to the tubing. Alternatively, the multivitamins may be added to the lipid infusate (<LINK REF="REF-Greene-1987" TYPE="REFERENCE">Greene 1987</LINK>). <LINK REF="REF-Kennedy-1997" TYPE="REFERENCE">Kennedy 1997</LINK> demonstrated improved serum retinol concentrations following intramuscular injections given three days per week. This route of administration has been adopted in several recent studies. In preterm infants who are able to tolerate enteral feeds, the absorption of enteral vitamin A by the immature gut may be poor.</P>
<P>An 'adequate' concentration of plasma vitamin A in very low birth weight (VLBW) infants is not known. Concentrations below 200 &#956;g/L (0.70 &#956;mol/L) have been considered deficient in premature infants, and concentrations below 100 &#956;g/L (0.35 &#956;mol/L) indicate severe deficiency and depleted liver stores. Both the plasma RBP response (<LINK REF="REF-Shenai-1990" TYPE="REFERENCE">Shenai 1990</LINK>) and the relative rise in serum retinal concentration (<LINK REF="REF-Zachman-1996" TYPE="REFERENCE">Zachman 1996</LINK>) following intramuscular vitamin A administration have been described as useful tests to assess functional vitamin A status. However, in a recent review <LINK REF="REF-Mactier-2005" TYPE="REFERENCE">Mactier 2005</LINK> concluded that the relationship between measures of vitamin A concentration and functional vitamin A status is not clear in preterm infants.</P>
<P>Vitamin A deficiency in laboratory animals produces a sequence of histopathological changes in the respiratory tract epithelium including necrotising tracheobronchiolitis and squamous metaplasia. These changes can be reversed by restoration of an adequate vitamin A status. Similar changes are observed in ventilated infants with chronic neonatal lung injury, leading to the suggestion that vitamin A deficiency may contribute to such injury and supplementation with vitamin A may facilitate healing and recovery (<LINK REF="REF-Chytil-1992" TYPE="REFERENCE">Chytil 1992</LINK>; <LINK REF="REF-Shenai-1993" TYPE="REFERENCE">Shenai 1993</LINK>). Two earlier studies reported that VLBW infants who developed chronic lung disease had lower concentrations of vitamin A than similar infants without chronic lung disease (<LINK REF="REF-Hustead-1984" TYPE="REFERENCE">Hustead 1984</LINK>; <LINK REF="REF-Shenai-1985" TYPE="REFERENCE">Shenai 1985</LINK>), although other studies from an era when all infants received more adequate supplementation have given conflicting results (<LINK REF="REF-Chabra-1994" TYPE="REFERENCE">Chabra 1994</LINK>; <LINK REF="REF-Spears-2004" TYPE="REFERENCE">Spears 2004</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-11-14 05:47:46 -0500" MODIFIED_BY="[Empty name]">
<P>In the 1920s, vitamin A was considered to be an anti-infective agent. There is increasing evidence that vitamin A does have a role in immune function (<LINK REF="REF-Bates-1995" TYPE="REFERENCE">Bates 1995</LINK>). Several studies in areas of the world where there is generally poor nutritional status have suggested vitamin A supplementation in infancy may be associated with decreased mortality and morbidity. In infants in Indonesia, <LINK REF="REF-Humphrey-1996" TYPE="REFERENCE">Humphrey 1996</LINK> reported that a single dose of 52 &#956;mol (50,000 IU) given orally to term infants at birth reduced infant mortality and the prevalence of severe respiratory infections compared with placebo. A Cochrane review concluded that two oral doses of 200,000 IU in children under two years of age with measles was associated with a reduced risk of overall mortality and of pneumonia-specific mortality (<LINK REF="REF-Huiming-2005" TYPE="REFERENCE">Huiming 2005</LINK>).</P>
<P>Vitamin A has a role early in gestation in the development of the cardiovascular system (<LINK REF="REF-Mactier-2005" TYPE="REFERENCE">Mactier 2005</LINK>). Animal models suggest higher vitamin A concentrations may accelerate postnatal constriction of the ductus arteriosus. The possibility that vitamin A supplementation may ameliorate other complications of prematurity, including retinopathy, intraventricular haemorrhage, and necrotising enterocolitis, has been suggested by a number of authors, although the basis for any effect is not clearly established.</P>
<P>Vitamin A is potentially toxic and raised intracranial pressure and vomiting have been described in infants receiving large doses. In children and adults, chronic hypervitaminosis A may include bone and joint pain, mucocutaneous lesions, and hepatic dysfunction, but the syndrome has not been recognised in preterm infants.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-15 11:40:21 -0400" MODIFIED_BY="Heather Maxwell">
<P>Although a role for vitamin A in neonatal chronic lung disease is not in doubt, uncertainty exists regarding the efficacy of supplementation and whether additional benefit may be obtained by achieving concentrations beyond sufficiency.</P>
<P>This is an update of previous versions of this Cochrane Review (<LINK REF="REF-Darlow-1998" TYPE="REFERENCE">Darlow 1998</LINK>; <LINK REF="REF-Darlow-2000" TYPE="REFERENCE">Darlow 2000</LINK>; <LINK REF="REF-Darlow-2002" TYPE="REFERENCE">Darlow 2002</LINK>; <LINK REF="REF-Darlow-2007" TYPE="REFERENCE">Darlow 2007</LINK>; <LINK REF="REF-Darlow-2011" TYPE="REFERENCE">Darlow 2011</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>To evaluate supplementation with vitamin A on the incidence of death or neonatal chronic lung disease and long-term neurodevelopmental disability in very low birth weight (VLBW) infants compared with a control (placebo or no supplementation), and to consider the effect of the supplementation route, dose, and timing.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-08-16 10:34:30 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-08-16 10:16:36 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-07-29 14:01:54 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>Very low birth weight (VLBW) infants (defined as birth weight &#8804; 1500 grams or less than 32 weeks' gestation).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-19 12:48:06 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Vitamin A supplementation compared with control (placebo or no supplementation)</LI>
<LI>Different vitamin A supplementation dosage regimens</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-08-16 10:16:36 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-08-16 10:08:45 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death (at 28 days and at hospital discharge)</LI>
<LI>Chronic lung disease (defined as oxygen use at 28 days or at 36 weeks' postmenstrual age)</LI>
<LI>Death or chronic lung disease (defined as oxygen use at 28 days or at 36 weeks' postmenstrual age)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-08-16 10:16:36 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Vitamin A concentration (for studies comparing vitamin A dosage)</LI>
<LI>Nosocomial infection</LI>
<LI>Patent ductus arteriosus*</LI>
<LI>Necrotising enterocolitis*</LI>
<LI>Intraventricular haemorrhage (any intraventricular haemorrhage or severe intraventricular haemorrhage grades 3 and 4) (<LINK REF="REF-Papile-1978" TYPE="REFERENCE">Papile 1978</LINK>)*</LI>
<LI>Periventricular leukomalacia*</LI>
<LI>Retinopathy of prematurity (any, or requiring laser therapy)**</LI>
<LI>Neurodevelopment at 18 to 24 months</LI>
<LI>Death at 18 to 24 months**</LI>
<LI>Death or neurodevelopmental impairment at 18 to 24 months**</LI>
<LI>Adverse effects, including manifestations of hypervitaminosis A, particularly raised intracranial pressure and mucocutaneous lesions</LI>
</UL>
<P>*<I> Additional secondary outcomes added in the 2010 update</I>
</P>
<P>** <I>Additional secondary outcomes added in the 2016 update</I>
</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-08-16 10:17:51 -0400" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see <A HREF="http://neonatal.cochrane.org/resources-review-authors">the Cochrane Neonatal Group search strategy for specialized register</A>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-08-02 19:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>We conducted a comprehensive search including: the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, Issue 4, 2016; MEDLINE via PubMed (1966 to 1 May 2016); EMBASE (1980 to 1 May 2016); CINAHL (1982 to 1 May 2016). We used the following search terms: (vitamin A or retinol), plus database-specific limiters for RCTs and neonates (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the full search strategies for each database).</P>
<P>We applied no language restrictions. We searched the reference lists of any articles selected for inclusion in this review in order to identify additional relevant articles.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-08-16 10:17:51 -0400" MODIFIED_BY="[Empty name]">
<P>We handsearched issues of paediatric and nutritional journals and abstracts from the Pediatric Academic Societies' Annual Meeting from 2002 to 2010. We also searched for conference abstracts from Pediatric Academic Societies (PAS) and the European Society for Paediatric Research (ESPR). Searches were carried out in Abstracts to View (2000 to 2014) and Pediatric Reseach.</P>
<P>We searched clinical trials registries for ongoing or recently completed trials (<A HREF="https://www.clinicaltrials.gov/">clinicaltrials.gov</A>; the World Health Organization&#8217;s International Trials Registry and Platform <A HREF="http://www.whoint/ictrp/search/en/">www.whoint/ictrp/search/en/</A>; and <A HREF="http://www.isrctn.com/">the ISRCTN Registry</A>) without date limits up to May 2016.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-08-16 10:34:30 -0400" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-08-16 10:18:17 -0400" MODIFIED_BY="[Empty name]">
<P>We included all trials fulfilling the review's selection criteria. We cited all identified articles and made the decision regarding inclusion or exclusion of the studies by consensus. In the event of disagreements, we sought the opinion of a third party (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-08-16 10:34:30 -0400" MODIFIED_BY="[Empty name]">
<P>For each included study, we collected information regarding the method of randomisation, blinding, drug intervention, stratification, trial location, and whether the trial was conducted at a single centre or multiple centres. We also collected information regarding inclusion criteria, including gestational age and postnatal age at the time of treatment. The list of data extraction fields for the trial interventions and outcomes are shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>We completed data collection sheets before comparing them and resolving any discrepancies by referring to the original sources. For each study, one review author entered the final and agreed data into <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK> and a second review author checked the data. We referred to a third party to resolve any disagreements.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-08-02 13:06:33 -0400" MODIFIED_BY="[Empty name]">
<P>For the 2010 and 2016 updates, one author assessed the risk of bias in the included studies according to the methods in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This built on the previous version's assessment of the methodological quality of the included studies. Any uncertainties were resolved through discussion with a second author.</P>
<P>We assessed the following factors and judged them as having a high, low, or unclear risk of bias using the criteria in <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>:</P>
<UL>
<LI>Sequence generation (checking for possible selection bias)</LI>
<LI>Allocation concealment (checking for possible selection bias)</LI>
<LI>Blinding (checking for possible performance bias and detection bias)</LI>
<LI>Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</LI>
<LI>Selective outcome reporting (whether all of the study&#8217;s pre-specified outcomes were reported (by checking the trial protocol if available) or whether the study failed to include results of a key outcome that would have been expected to have been reported)</LI>
<LI>Other biases (including source of funding and sample size calculation)</LI>
</UL>
<P>For each item, and where possible, we have provided a supporting quotation from the trial article.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-08-02 19:19:34 -0400" MODIFIED_BY="[Empty name]">
<P>We conducted separate analyses for each of the following outcomes: neonatal death; chronic lung disease; retinopathy of prematurity; sepsis (one or more defined episodes); and neurodevelopmental disability. Since there were only a small numbers of deaths, we conducted analyses using the composite endpoints of neonatal chronic lung disease or death, and neurodevelopmental disability or death. All analyses were conducted on an intention-to-treat basis. We stratified the analyses by route of vitamin A administration.</P>
<P>For dichotomous outcomes, we analysed the effect of vitamin A supplementation via both the risk ratio (RR) and the risk difference (RD) with 95% confidence intervals (CI). From 1/RD we calculated the number need to treat to benefit (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). For vitamin A concentrations the intention was to focus the analysis on the mean difference between the supplemented and control groups. We combined continuous data using the standardised mean difference (SMD) and 95% CI.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-07-31 11:21:24 -0400" MODIFIED_BY="[Empty name]">
<P>We assessed between-study heterogeneity using the standard Chi² test and the I² statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-08-16 10:21:14 -0400" MODIFIED_BY="[Empty name]">
<P>We performed the meta-analysis using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. We used the Mantel-Haenszel method for estimates of the pooled RR and RD. For measured quantities we used the inverse variance method. We used the fixed-effect model for all meta-analyses.</P>
<P>Pooled estimates of the effects and corresponding 95% confidence interval of the outcomes of neonatal death, chronic lung disease (oxygen use at 28 days in survivors), death or chronic lung disease (oxygen use at 28 days), death before 36 weeks' postmenstrual age, chronic lung disease (oxygen use at 36 weeks' postmenstrual age in survivors) and neurodevelopmental disability at 18 to 22 months are included in the 'Summary of findings' tables in which the summary of the assessment of the evidence found for each outcome is presented.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>For the 2016 update, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the GRADE Handbook (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>), to assess the quality of evidence for the following (clinically relevant) outcomes: neonatal death; chronic lung disease at 28 days and 36 weeks' postmenstrual age; death or chronic lung disease at 28 days and 36 weeks' postmenstrual age; and neurodevelopmental impairment at 18 to 22 months.</P>
<P>Two authors independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from randomised controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias); consistency across studies; directness of the evidence; precision of estimates; and presence of publication bias. We used the <LINK REF="REF-GRADEpro_x002d_GDT-2013" TYPE="REFERENCE">GRADEpro-GDT 2013</LINK> Guideline Development Tool to create a &#8216;Summary of findings&#8217; table to report the quality of the evidence.</P>
<P>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades:</P>
<OL>
<LI>High: We are very confident that the true effect lies close to that of the estimate of the effect.</LI>
<LI>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</LI>
<LI>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.</LI>
<LI>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.</LI>
</OL>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-07-21 06:10:48 -0400" MODIFIED_BY="[Empty name]">
<P>If data were available, we planned subgroup analyses to address the effect of the route, dose, and timing of supplementation.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-12-17 12:38:42 -0500" MODIFIED_BY="[Empty name]">
<P>Where appropriate, we planned sensitivity analyses to explore the impact of the risk of bias assessments.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-08-16 10:34:56 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-08-16 10:28:23 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Results of the search</HEADING>
<P>We identified 21 potentially relevant trials of which 11 met the eligibility criteria (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). Ten trials compared vitamin A with a control, while one trial compared three different vitamin A dosing regimens and had a primary outcome of serum retinol concentrations at 28 days (<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>); see trial details in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>We excluded ten trials from the review (<LINK REF="STD-Aranda-1992" TYPE="STUDY">Aranda 1992</LINK>; <LINK REF="STD-Landman-1992" TYPE="STUDY">Landman 1992</LINK>; <LINK REF="STD-Koo-1993" TYPE="STUDY">Koo 1993</LINK>; <LINK REF="STD-Robbins-1993" TYPE="STUDY">Robbins 1993</LINK>; <LINK REF="STD-Rush-1994" TYPE="STUDY">Rush 1994</LINK>; <LINK REF="STD-Coutsoudis-1996" TYPE="STUDY">Coutsoudis 1996</LINK>; <LINK REF="STD-Coutsoudis-2000" TYPE="STUDY">Coutsoudis 2000</LINK>; <LINK REF="STD-Aurvag-2007" TYPE="STUDY">Aurvag 2007</LINK>; <LINK REF="STD-Longardt-2014" TYPE="STUDY">Longardt 2014</LINK>; <LINK REF="STD-Schmiedchen-2016" TYPE="STUDY">Schmiedchen 2016</LINK>) (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'). <LINK REF="STD-Robbins-1993" TYPE="STUDY">Robbins 1993</LINK> was not a randomised controlled trial. <LINK REF="STD-Coutsoudis-1996" TYPE="STUDY">Coutsoudis 1996</LINK> and <LINK REF="STD-Coutsoudis-2000" TYPE="STUDY">Coutsoudis 2000</LINK> enrolled low birth weight infants of less than 36 weeks' gestation and the primary outcome was the incidence of respiratory infections in the first year of life. <LINK REF="STD-Aurvag-2007" TYPE="STUDY">Aurvag 2007</LINK> compared vitamin A supplementation using human milk fortifier with historical controls and did not report clinical outcomes. Four studies were studies of pharmacodynamics that reported vitamin A concentrations but not clinical outcomes (<LINK REF="STD-Aranda-1992" TYPE="STUDY">Aranda 1992</LINK>; <LINK REF="STD-Landman-1992" TYPE="STUDY">Landman 1992</LINK>; <LINK REF="STD-Koo-1993" TYPE="STUDY">Koo 1993</LINK>; <LINK REF="STD-Rush-1994" TYPE="STUDY">Rush 1994</LINK>). The unpublished study by <LINK REF="STD-Aranda-1992" TYPE="STUDY">Aranda 1992</LINK> did not state the route of vitamin A supplementation and the reported vitamin A levels appeared to contain a decimal point error. <LINK REF="STD-Landman-1992" TYPE="STUDY">Landman 1992</LINK> and <LINK REF="STD-Rush-1994" TYPE="STUDY">Rush 1994</LINK> compared equivalent doses of vitamin A administered either enterally or intramuscularly. The data in <LINK REF="STD-Rush-1994" TYPE="STUDY">Rush 1994</LINK> were only reported graphically. <LINK REF="STD-Koo-1993" TYPE="STUDY">Koo 1993</LINK> compared three doses of vitamin A added to preterm formula, which were given for an unstated period of time.</P>
<P>
<LINK REF="STD-Longardt-2014" TYPE="STUDY">Longardt 2014</LINK> was not a randomised controlled trial and reported on serum retinol, retinyl palmitate, total retinol-binding protein 4 (RBP4), retinol-unbound RBP4 (apo-RBP4) and transthyretin concentrations. Clinically relevant outcomes were not reported.</P>
<P>
<LINK REF="STD-Schmiedchen-2016" TYPE="STUDY">Schmiedchen 2016</LINK> studied the impact of urinary retinol excretion on the serum retinol concentration of 63 VLBW infants treated with vitamin A (5000 IU intramuscular, 3 times/week for 4 weeks) compared to 38 untreated infants classified as control group. The groups were not randomised. See trial details in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>
<LINK REF="STD-Calisici--2014" TYPE="STUDY">Calisici 2014</LINK> is published only as an abstract and is awaiting further assessment. See trial details in the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial location and size</HEADING>
<P>Most trials were conducted in the USA (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>). Three trials were conducted in Europe: in Greece (<LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>); and the UK (<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>). One trial was conducted in South Africa (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>); and one trial was conducted in Thailand (<LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>).</P>
<P>Most trials included fewer than 100 infants (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). Two included between 100 and 200 participants (<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>); and one trial included 807 infants (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A versus control</HEADING>
<P>The ten trials comparing vitamin A with a control reported outcomes for 1460 infants, 735 treated with vitamin A and 725 control infants.</P>
<P>
<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>: Single centre randomised controlled trial. Enrolled 40 infants, birth weight 700 to 1300 grams and gestational age 26 to 30 weeks, requiring supplemental oxygen and mechanical ventilation for at least 72 hours in the first week; Caucasian infants only; birth weight appropriate for gestational age; no congenital abnormalities.</P>
<P>
<LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>: Single centre randomised controlled trial. Enrolled 55 infants with birth weight &#8804; 1300 grams; gestation &lt; 29 weeks; requirement for &gt; 40% oxygen and mechanical ventilation for &gt; 72 hours in first week.</P>
<P>
<LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>: Multicentre randomised controlled trial. Enrolled 49 infants with birth weight 700 to 1100 grams requiring supplemental oxygen and mechanical ventilation between 72 and 96 hours of age with previous cumulative duration of ventilation and oxygen &gt; 48 hours. Infants with growth restriction (undefined), congenital or chromosomal abnormalities, hydrops fetalis, congenital infection, neonatal hepatitis or 'do not resuscitate' order were excluded.</P>
<P>
<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>: Single centre randomised controlled trial. Enrolled 60 infants with birth weight between 1000 and 1500 grams; gestational age of &#8804; 34 weeks; infants were receiving supplemental oxygen and mechanical ventilation for at least 72 hours during the first week; no congenital anomalies or infection; black South African infants.</P>
<P>
<LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>: Single centre randomised controlled trial. Enrolled 86 infants with birth weight 725 to 1300 grams, age &lt; 96 hours; no intraventricular or periventricular haemorrhage, history of maternal substance abuse, or sexually transmitted disease; no congenital anomalies.</P>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>: Multicentre randomised controlled trial. Enrolled 807 infants with birth weight 401 to 1000 grams requiring supplemental oxygen or mechanical ventilation at 24 hours of age; and no major congenital anomalies, non-bacterial infection, or terminal illness.</P>
<P>
<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>: Multicentre randomised controlled trial. Enrolled 154 infants with birth weight &lt; 1000 grams; no life-threatening congenital abnormalities; consent before 24 hours of age.</P>
<P>
<LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>: Single centre randomised controlled trial. Enrolled 40 infants with birth weight 500 to 1500 grams; gestation &lt; 32 weeks; having indwelling umbilical line; no major congenital malformations or chromosomal anomalies; and &lt; 24 hours of age.</P>
<P>
<LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>: Double-blind, randomised controlled trial conducted at three neonatal centres in Glasgow. Enrolled 89 infants (42 supplemented and 47 controls) &lt; 32 weeks' gestation or &lt; 1501 grams birth weight, or both.</P>
<P>Supplemented infants received additional intramuscular vitamin A 10,000 IU 3 times weekly from day 2 for a minimum of 2 weeks or until establishment of oral feeding.</P>
<P>
<LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>: Randomised controlled trial to assess the effect of vitamin A supplementation for prevention of bronchopulmonary dysplasia in VLBW premature infants. Eighty premature infants weighing &lt; 1500 grams who received mechanical ventilation or oxygen supplementation at 24 hours of age and admitted to Neonatal units of Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A dosing regimens</HEADING>
<P>
<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>: Single centre randomised controlled trial evaluating vitamin A dosage. Enrolled 120 infants, birth weight between 401 and 1000 grams; requiring mechanical ventilation or supplemental oxygen at 24 hours of age; and no major congenital anomalies, non-bacterial infection, or terminal illness. <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> used the same entry criteria as <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A versus control</HEADING>
<P>Ten trials compared vitamin A with a control. All but <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> and <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> gave supplemental vitamin A (water-soluble retinyl palmitate) by intramuscular injection soon after birth, usually day four, and over the next 28 days. The trials varied in the vitamin A dose and regimen.</P>
<P>
<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>: Vitamin A (water-soluble retinyl palmitate) versus control</P>
<P>Supplemental 2000 IU vitamin A by intramuscular injection alternate days from day 4 for a total of 14 injections (n = 20) compared to normal saline placebo (n = 20)</P>
<P>Other: both control and study infants received vitamin A 400 IU/dL in parenteral nutrition and 240 to 550 IU/dL from milk plus 1500 IU supplements when fed orally</P>
<P>
<LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>: Vitamin A (water-soluble retinyl palmitate) versus control</P>
<P>Supplemental 4000 IU vitamin A intramuscular injection from day 4 to 6 on alternate days until extubated (n = 27) compared to normal saline placebo (n = 28).</P>
<P>
<LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>: Vitamin A (water-soluble retinyl palmitate) versus control</P>
<P>Supplemental 2000 IU vitamin A by intramuscular injection alternate days from day 4 for 14 doses (n = 27) compared to normal saline placebo or mock injection (n = 22)</P>
<P>Other: both control and study infants received 1200 to 1500 IU/d vitamin A in protein-dextrose solution when on parenteral nutrition; when fed orally all infants received vitamin A 250 to 1030 IU/100 mL milk; antenatal steroids received by 26% infants in the vitamin A group and 41% in the control group; &gt; 90% received an artificial surfactant</P>
<P>
<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>: Vitamin A (water-soluble retinyl palmitate) versus control</P>
<P>Supplemental 4000 IU vitamin A intramuscular injection 3 times a week from day 4 for a total of 12 injections (n = 31); no supplementation (n = 29)</P>
<P>Other: some control and study infants received vitamin A 1500 to 3000 IU after 1 week of age when fed orally</P>
<P>
<LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>: Vitamin A (retinyl palmitate) versus control</P>
<P>Supplemental vitamin A 80,000 RE/L (giving about 1300 to 3300 IU/kg/d) in intravenous lipid infused over 16 h from randomisation (48 to 96 hours) and while receiving parenteral nutrition (n = 44) compared to no supplementation (n = 42)</P>
<P>Other: both control and study infants received vitamin A as multivitamin preparation added to protein-dextrose solution (birth weight &lt; 1000 grams 1.5 mL/d, 210 RE/d; &gt; 1000 grams 3.4 mL/d, 476 RE/d) and oral supplements when fed orally</P>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>: Vitamin A (water-soluble retinyl palmitate) versus control</P>
<P>Supplemental 5000 IU vitamin A intramuscular injection 3 times a week for 4 weeks (n = 405) compared to sham injection (n = 402)</P>
<P>Other: control and study infants received similar intakes of vitamin A from non-study enteral and parenteral sources but amounts not stated; antenatal steroids received by 76% of infants in the vitamin A group and 74% in the control group; &gt; 80% received a natural surfactant</P>
<P>
<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>: Vitamin A (form not stated) versus control</P>
<P>Supplemental 5000 IU vitamin A orally daily until day 28 (n = 77) compared to same volume look-alike placebo liquid (n = 77)</P>
<P>Other: control and study infants received 23 IU/kg/d vitamin A (stated amount but probably 233 IU) in intralipid when on parenteral nutrition; when on full enteral feeds and more than 14 days of age all infants received 5000 IU/kg/d vitamin A orally; antenatal steroids received by 77% in the vitamin A group and 82% in the control group; all but 1 infant in the control group received an artificial surfactant</P>
<P>
<LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>: Vitamin A (water-miscible preparation of vitamin A (Aquasol A)) versus control</P>
<P>Supplemental 1500 to 3000 IU vitamin A (based on weight) by intramuscular injection on days 1, 3 and 7 (n = 22) compared to sham injection (n = 18)</P>
<P>Other: most infants received parenteral nutrition including 466 IU/dL vitamin A and an additional 1000 IU supplement when fed orally; antenatal steroids received by 86% of infants in the vitamin A group and 72% in the control group</P>
<P>
<LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>: Supplemented infants received additional intramuscular vitamin A 10,000 IU 3 times weekly from day 2 for a minimum of 2 weeks or until establishment of oral feeding.</P>
<P>
<LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>: Infants were assigned to receive either intramuscular vitamin A 5000 IU 3 times/week (treatment group) or sham procedure (control group) for four weeks.</P>
<P>Study and control infants were also administered standard vitamin A. However, the amount of vitamin A in standard therapy, and hence received by the control groups, varied between studies. When on parenteral nutrition infants in <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> received vitamin A 400 IU/100 mL of protein-dextrose infusion and usually less than 700 IU/kg/d from all sources. Infants in <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> received 1200 to 1500 IU/d of vitamin A in the protein-dextrose solution. In <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>, infants on parenteral nutrition received no vitamin A but some received 1500 to 3000 IU/d after one week when fed orally. In <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>, the amount of standard vitamin A was not stated. In <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>, standard vitamin A was added to the protein-dextrose solution, with infants less than 1000 grams receiving 700 IU/d and infants more than 1000 grams receiving 1580 IU/d. In <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>, infants received approximately 700 IU/kg/d in the first week, principally in protein-dextrose solution, and closer to 1000 IU/kg/d in weeks two to four from all sources (data estimated from a graph). Infants in <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> were stated to receive 23 IU/kg/d added to intralipid when on parenteral nutrition (however, the standard UK dose at that time was 233 IU/kg/d and it was probable that infants in this study received this dose) and 5000 IU/kg/day orally when on full enteral feeds from the 14th postnatal day. In <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>, most infants on parenteral nutrition received 466 IU vitamin A added to 100 mL of the protein-dextrose solution, and 1500 IU/d orally when fully enterally fed. In <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>, infants on parenteral nutrition received routine fat soluble vitamins as part of their lipid infusion (Vitlipid N). Lipid infusion was stopped once the infants had achieved 75% of their expected enteral intake and all infants received oral supplementation of vitamin A on day 14 of life if tolerating enteral feeds.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A dosing regimens</HEADING>
<P>
<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>: Infants were randomised to receive a standard vitamin A supplement by 5000 IU intramuscular injection of vitamin A on three days per week for four weeks (considered as the control group) (n=40), a higher dose of 10,000 IU on three days per week for four weeks (n = 40), or a once-per-week dose of 15,000 IU for four weeks (n = 40).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>We contacted several trial authors for further details about the trial outcomes and data. <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK> gave complete data, published in an earlier abstract from 1990, and we sought and obtained further clarification from the trial authors concerning two outcomes: oxygen use at one month in survivors; and death or oxygen use at one month. We were able to update the data of <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> with information provided by the trial author to Dr K Kennedy at the time of an earlier review (<LINK REF="REF-Kennedy-1997" TYPE="REFERENCE">Kennedy 1997</LINK>). We obtained information on the age of infants at death from the corresponding author of <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>. Further information on the numbers examined for retinopathy of prematurity and numbers with any retinopathy in <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> were provided by the trial author. We also received further information on the timing of death, numbers of infants having serum retinol estimations at 28 days, and any retinopathy of prematurity from the author of <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A versus control</HEADING>
<P>
<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>: Death before 31 days, bronchopulmonary dysplasia (oxygen requirement or ventilation at 31 days plus characteristic chest x-ray), total days' oxygen, episodes of sepsis, retinopathy of prematurity, and vitamin A levels.</P>
<P>
<LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>: Death before 31 days, bronchopulmonary dysplasia (oxygen requirement and characteristic chest x-ray on day 31) and vitamin A levels. Unpublished data of <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> were available for 28, 29, 30 and 31 days.</P>
<P>
<LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>: Death before 31 days, bronchopulmonary dysplasia (oxygen requirement at 31 days and characteristic chest x-ray), oxygen requirement at 34 weeks' post-conceptual age, retinopathy of prematurity, plasma vitamin A levels and retinyl binding protein at various times.</P>
<P>
<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>: Death before 31 days, bronchopulmonary dysplasia (oxygen or ventilation on day 31 and characteristic chest x-ray; full data obtained from trial authors), culture-proven sepsis, vitamin A levels at various times.</P>
<P>
<LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>: Bronchopulmonary dysplasia (oxygen beyond 28 days and characteristic chest x-ray, total days' oxygen requirement, vitamin A and retinol-binding protein levels at various times.</P>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>: Oxygen requirement at, or death before, 36 weeks' postmenstrual age; oxygen requirement at, or death before, 28 days of age; culture-proven sepsis; grade 3 or 4 intracranial haemorrhage; periventricular leukomalacia; vitamin A on study day 28 in subset of infants and relative dose-response to 2000 IU vitamin A intramuscular. Examination for potential toxicity weekly. Assessment of neurodevelopmental status at 18 to 22 months' corrected age is available in Ambalavanan 2005 (companion paper for <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>). Additional subgroup analysis of 'small for gestational age' infants.</P>
<P>
<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>: Oxygen requirement at 28 days, death pre-discharge, oxygen requirement at 36 weeks' postmenstrual age, retinopathy of prematurity requiring treatment. <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> also reported on a patent ductus arteriosus requiring treatment with indomethacin or surgical closure, but the timing of this was uncertain as to whether some infants had died before this outcome; hence we did not include these data.</P>
<P>
<LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>: Failure of patent ductus arteriosus closure, defined as patent ductus arteriosus larger than trivial on day 14, indomethacin treatment, or surgical ligation. <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> also reported deaths (and further information on the timing of these was obtained from the trial authors) and oxygen requirement at 36 weeks' postmenstrual age.</P>
<P>
<LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>: Hepatic stores were assessed by relative dose response (RDR). The primary outcome measure was cone-corrected dark-adapted retinal rod sensitivity measured by electroretinogram at 36 weeks' postmenstrual age (PMA). Complications of prematurity were reported including use of respiratory support, intraventricular haemorrhage, retinopathy of prematurity, supplemental oxygen at 36 weeks' postmenstrual age, and death</P>
<P>
<LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>: The investigators reported on serum vitamin A levels, and complications of prematurity including supplemental oxygen at 36 weeks postmenstrual age, duration of intubation, days on oxygen therapy, and length of hospital stay.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A dosing regimens</HEADING>
<P>The primary outcome measure for the trial by <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> was serum retinol concentrations in &#956;g/L at 28 days. <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> also reported on death before 36 weeks' postmenstrual age, oxygen requirement at or death before 36 weeks' postmenstrual age, and threshold retinopathy of prematurity. We obtained further information on timing of death, numbers of infants having serum retinol estimations, and any retinopathy of prematurity from the trial authors.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-08-16 10:01:44 -0400" MODIFIED_BY="[Empty name]">
<P>Full details of the 'Risk of bias' assessment are available by trial in the '<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>' tables and are summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2016-07-19 13:49:57 -0400" MODIFIED_BY="[Empty name]">
<P>Of the 11 included trials, eight used adequate methods to generate the allocation sequence and seven used adequate methods to conceal allocation (low risk of bias). <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> and <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> did not provide details to allow this risk of bias component to be assessed, and <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK> provided details only for the sequence generation method (computer-generated random numbers).</P>
<P>
<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> used shuffled blocks of sealed opaque envelopes for randomisation and stratified randomisation by birth weight. The randomisation and allocation for <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>, <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>, <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>, <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>, <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK> and <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> were conducted by someone outside of the trial team and used sealed envelopes.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-12-07 12:22:56 -0500" MODIFIED_BY="[Empty name]">
<P>Six trials blinded participants to the intervention and outcome assessors (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>, for example, used opaque tape to conceal the contents of the syringes and reported that the &#8220;staff responsible for patient care had no knowledge of group designation&#8221;.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-11-15 00:11:37 -0500" MODIFIED_BY="[Empty name]">
<P>All but <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> and <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> had complete follow-up of participants. <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> did not report outcomes on all infants entered into the study as they excluded 10 who transferred to another centre for surgery and two who died, for whom group assignment was not stated. For <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>, no information was available in the study abstract.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-11-15 00:11:58 -0500" MODIFIED_BY="[Empty name]">
<P>Most trials were free of selective reporting in that it was clear that all of the trial&#8217;s pre-specified outcome measures and all expected outcome measures of interest to the review were reported. This was unclear for <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> because only a study abstract (from a conference proceedings) was available, while <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> did not report all outcome measures of interest.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-08-02 19:19:34 -0400" MODIFIED_BY="[Empty name]">
<P>This item was evaluated in relation to information about trial funding (such as industry funding) and sample size calculation. <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> appeared to be free of these sources of bias because the study protocol was described in detail, including the sample size calculation, and the trial was free of industry funding. <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK> was funded by the Chief Scientific Office, Scotland, and appeared to be free of other potential sources of bias. <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> and <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> were assessed as having a high risk of bias for this component: <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> because little information was available in the abstract; and <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> because few of the eligible infants were enrolled in the trial. Information about this item for the 'Risk of bias' assessment was unclear in the other studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-08-16 10:34:56 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: Supplemental vitamin A versus no supplementation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Neonatal death (Outcome 1.1)</HEADING>
<P>Six trials reported on neonatal death (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>); none showed a significant difference between the vitamin A and control groups. The meta-analysis does not support a reduction of the risk of neonatal death associated with receiving vitamin A (typical RR 0.86, 95% CI 0.66 to 1.11; typical RD &#8722;0.02, 95% CI &#8722;0.06 to 0.02; 1165 infants) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).The quality of evidence for this outcome is moderate because of imprecision of estimates of effect (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic lung disease (oxygen use at 28 days in survivors) (Outcome 1.2)</HEADING>
<P>Seven trials (the six trials above plus <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>) reported on chronic lung disease at 28 days. Only one study (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>) reported a statistically significant difference between intervention groups. The largest trial showed an important trend to no differences between treatment arms (RR 0.97, 95% CI 0.89 to 1.06; 718 infants) (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>). The meta-analysis of these seven studies showed a trend towards a reduced risk of chronic lung disease between treatment arms (typical RR 0.93, 95% CI 0.86 to 1.01; typical RD &#8722;0.05, 95% CI &#8722;0.10 to 0.00; 1070 infants) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The overall quality of the evidence for this outcome was judged as moderate; we downgraded the quality of evidence based upon imprecision because although the 95% CI for the typical RR is narrow the result is consistent with minimal clnical effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death or chronic lung disease (oxygen use at 28 days) (Outcome 1.3)</HEADING>
<P>Data for the combined outcome of death or chronic lung disease at 28 days were available in six trials (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>). Only one study reported a statistically significant difference in this outcome (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>). When the meta-analysis was confined to the five trials reporting on supplementation via intramuscular injection (excluding <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>) there was a trend towards a reduction in death or oxygen use at one month that was of borderline statistical significance (typical RR 0.93, 95% CI 0.86 to 1.00; typical RD &#8722;0.06, 95% CI &#8722;0.11 to &#8722;0.00; NNTB 17, 95% CI 9 to 1000+; 1011 infants) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). When <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> (in which oral vitamin A supplementation was given to treated infants) was included in the meta-analysis the pooled data showed a significant reduction in this outcome (typical RR 0.93, 95% CI 0.88 to 0.99; typical RD &#8722;0.05, 95% CI &#8722;0.10 to &#8722;0.01; NNTB 20, 95% CI 10 to 100; 1165 infants, I² = 37%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The overall quality of the evidence for this outcome was judged as moderate; we downgraded the quality of evidence based upon imprecision because although the 95% CI for the typical RR is narrow the result is consistent with minimal clnical effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death (before 36 weeks' postmenstrual age) (Outcome 1.4)</HEADING>
<P>Four trials reported on this outcome (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>). <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK> reported "death before discharge" (but not at 36 weeks' PMA) and therefore is not included in this analysis. The polled estimate of the effect showed no significant differences between the vitamin A and control groups (typical RR 1.00, 95% CI 0.77 to 1.29; 1089 infants) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The overall quality of the evidence for this outcome is moderate because of imprecision in estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic lung disease (oxygen use at 36 weeks' postmenstrual age) (Outcome 1.5)</HEADING>
<P>Five trials reported on this outcome (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> reported a marginal reduction in oxygen use at 36 weeks postmenstrual age in the vitamin A group (RR 0.85, 95% CI 0.73 to 0.98; RD &#8722;0.09, 95% CI &#8722;0.16 to &#8722;0.01; NNTB 11, 95% CI 6 to 100; 693 infants).</P>
<P>Similar results are seen in the pooled analysis, with a small beneficial effect of vitamin A on the risk of chronic lung disease at 36 weeks' postmenstrual age (typical RR 0.87, 95% CI 0.77 to 0.99; typical RD &#8722;0.07, 95% CI &#8722;0.13 to &#8722;0.01; NNTB 14, 95% CI 8 to 100; 986 infants) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The overall quality of the evidence for this outcome was judged as moderate; we downgraded the quality of evidence based upon imprecision because although the 95% CI for the typical RR is narrow the result is consistent with minimal clnical effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death or chronic lung disease (Oxygen use at 36 weeks' postmenstrual age) (Outcome 1.6)</HEADING>
<P>Four trials reported on this outcome (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>). <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> showed a trend towards reduction in death or chronic lung disease in the vitamin A group that was of borderline statistical significance (RR 0.89, 95% CI 0.79 to 1.00; RD &#8722;0.07, 95% CI &#8722;0.14 to 0.00). Pooling the data from the four trials did not meaningfully alter this finding (typical RR 0.92, 95% CI 0.84 to 1.01; typical RD &#8722;0.05, 95% CI &#8722;0.11 to 0.01; 1089 infants) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Including the outcome data at 34 weeks' postmenstrual age from <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> in this analysis, there was essentially no difference to these results. The overall quality of the evidence for this outcome was judged as moderate; we downgraded the quality of evidence based upon imprecision because although the 95% CI for the typical RR is narrow the result is consistent with minimal clnical effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death (at 18 to 24 months) (Outcome 1.7)</HEADING>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> reported on this outcome and found no significant difference between the vitamin A and control groups (RR 0.95, 95% CI 0.71 to 1.27; RD &#8722;0.01, 95% CI &#8722;0.06 to 0.04; 807 infants (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neurodevelopmental impairment at 18 to 24 months (Outcome 1.8)</HEADING>
<P>Ambalavanan 2005 followed up 88% of the surviving infants who participated in the <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> trial at 18 to 22 months corrected age. Forty-one infants could not be assessed, leaving 290 infants in the intervention group and 289 in the control group (15% lost to follow-up in both groups). There was no difference between the groups in either neurodevelopment impairment, defined as one or more of: Bayley II Mental Index less than 70, Psychomotor Index less than 70, any cerebral palsy, blind in both eyes, or bilateral hearing aids (RR 0.89, 95% CI 0.74 to 1.08; RD &#8722;0.05, 95% CI &#8722;0.04 to 0.03; 1538 infants) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The overall quality of the evidence for this outcome is moderate because of imprecision in estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death or neurodevelopmental impairment at 18 to 24 months (Outcome 1.9)</HEADING>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> reported on this outcome and found no significant differences between the vitamin A and control groups (RR 0.92, 95% CI 0.81 to 1.05; RD &#8722;0.05, 95% CI &#8722;0.12 to 0.03; 687 infants) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patent ductus arteriosus (Outcome 1.10)</HEADING>
<P>
<LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> found no significant difference in the failure of ductal closure or treatment by day 14 between the vitamin A and control groups (RR 0.98, 95% CI 0.56 to 1.72; RD &#8722;0.01, 95% CI &#8722;0.32 to 0.30; 40 infants) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
<P>
<LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK> reported on any evidence of PDA diagnosed by echocardiography but did not report rates of treatment between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sepsis (Outcome 1.11)</HEADING>
<P>Three trials reported on one or more episodes of culture-proven nosocomial sepsis (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). The pooled data showed a non-significant trend towards a reduction in sepsis in the vitamin A group (typical RR 0.89, 95% CI 0.76 to 1.04; typical RD &#8722;0.05, 95% CI &#8722;0.11 to 0.01; 947 infants) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Necrotising enterocolitis (Outcome 1.12)</HEADING>
<P>Four trials reported on necrotising enterocolitis (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>); and the pooled data showed no significant difference between the vitamin A and control groups (typical RR 0.92, 95% CI 0.67 to 1.27; typical RD &#8722;0.01, 95% CI &#8722;0.05 to 0.03; 1101 infants) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intraventricular haemorrhage (Outcome 1.13)</HEADING>
<P>Three trials reported on any intraventricular haemorrhage (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>). The pooled data found no significant difference between the vitamin A and control groups (typical RR 0.95, 95% CI 0.82 to 1.10; typical RD &#8722;0.02, 95% CI &#8722;0.09 to 0.04; 907 infants) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Four of the trials also reported on severe intraventricular haemorrhage (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). There was no significant difference between the vitamin A and control groups (typical RR 0.95, 95% CI 0.72 to 1.25; typical RD &#8722;0.01, 95% CI &#8722;0.05 to 0.04; 1035 infants) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Periventricular leukomalacia (Outcome 1.14)</HEADING>
<P>
<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> reported on this outcome and found no significant differences in periventricular leukomalacia between the vitamin A and control groups (RR 0.74, 95% CI 0.44 to 1.25; RD &#8722;0.01, 95% CI &#8722;0.05 to 0.03; 646 infants) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Retinopathy of prematurity (Outcome 1.15)</HEADING>
<P>Three trials reported on this outcome (<LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>; <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK>). Additional data was obtained from the trial author of <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>. <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> and <LINK REF="STD-Kiatchoosakun-2014" TYPE="STUDY">Kiatchoosakun 2014</LINK> noted a trend to reduced incidence of retinopathy of prematurity in the vitamin A group; this was reflected in the pooled trial data (typical RR 0.81, 95% CI 0.65 to 1.01; typical RD &#8722;0.10, 95% CI &#8722;0.20 to 0.00; 255 infants)(<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Retinopathy of prematurity requiring laser therapy (Outcome 1.16)</HEADING>
<P>Two trials reported on retinopathy of prematurity requiring laser therapy (<LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>). No difference was seen in the risk of retinopathy of prematurity requiring laser therapy (typical RR 1.27, 95% CI 0.55, 2.94; 236 infants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>The studies by <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>, <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK>, and <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> make no comment on monitoring for adverse effects. <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> noted that clinical monitoring for toxicity included periodic anterior fontanelle pressure assessment to detect raised intracranial pressure and reported no clinical or biochemical evidence of toxicity. <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> reported that intramuscular injections of vitamin A were painful, and both this trial and <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK> found no evidence of biochemical toxicity. <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> noted that the incidence of potential adverse effects, seizures, and persistent vomiting did not differ between the groups. Infants in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> were independently assessed for signs of toxicity on a weekly basis; a suspected or definite increase in fontanelle tension was slightly more frequent in control than supplemented infants (18% versus 15%, P = 0.26), and potential toxicity unexplained by other factors occurred in 0.8% controls and 1.0% supplemented infants.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin A dosing regimens</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: Vitamin A regimens: higher dose (10,000 IU) versus standard dose (5000 IU); both intramuscular and 3 <I>× </I>week for 4 weeks</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: Vitamin A regimens: once-a-week (15,000 IU) versus standard dose (5000 IU 3 x week); both intramuscular and for 4 weeks</HEADING>
<P>
<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> compared a 'standard' intramuscular regimen of supplemental vitamin A (5000 IU 3 × per week for 4 weeks) as used in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>, with a higher dose (10,000 IU 3 × per week for 4 weeks) and with a once-per-week dose (15,000 IU weekly for 4 weeks). The vitamin A was given intramuscularly, and the trial's primary outcome was the serum retinol concentration at 28 days</P>
<SUBSECTION>
<HEADING LEVEL="4">Death before 36 weeks' postmenstrual age (Outcomes 2.1 and 3.1)</HEADING>
<P>There was no significant difference for this outcome between the higher- and standard-dose groups (80 infants) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), or between the once-a-week and standard regimens (80 infants) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oxygen use at 36 weeks' postmenstrual age in survivors (Outcomes 2.2 and 3.2)</HEADING>
<P>There was no significant difference for this outcome between the higher- and standard-dose groups (61 infants) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), or between the once-a-week and standard regimens (61 infants, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death or oxygen use at 36 weeks' postmenstrual age (Outcomes 2.3 and 3.3)</HEADING>
<P>There was no significant difference for this outcome between the higher- and standard-dose groups (80 infants) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), or between the once-a-week and standard regimens (80 infants, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A concentration (retinol) (Outcomes 2.4, 2.5, 3.4 and 3.5)</HEADING>
<P>There was no significant difference between the standard dose and higher dose for this outcome when measured as retinol (&#956;g/L) on study day 28 (55 infants) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) or as retinol (&lt; 200 &#956;g/L) on day 28 (%) (55 infants) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>The once-per-week regimen resulted in significantly lower concentrations than the standard regimen on study day 28 (SMD &#8722;0.97, 95% CI -1.56 to &#8722;0.38; 50 infants (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). The once-per-week dose regimen also resulted in a higher proportion of infants with 28-day retinol concentrations below 200 &#956;g/L (RR 2.52, 95% CI 1.24 to 5.09; 50 infants) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Necrotising enterocolitis (Outcome 2.6 and 3.6)</HEADING>
<P>There were no significant differences for this outcome between the higher- and standard-dose groups (80 infants) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) or between the once-a-week and standard regimens (80 infants) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Retinopathy of prematurity (Outcomes 2.7, 2.8, 3.7 and 3.8)</HEADING>
<P>There was a trend to fewer infants with retinopathy of prematurity in the higher-dose group compared to the standard-dose group, for both any grade (63 infants)(<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>) and threshold disease (63 infants)(<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
<P>When we compared the once-a-week regimen with the standard regimen there was a trend to fewer infants with retinopathy of prematurity for any grade (64 infants) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) but there was no significant difference between the groups when measured as threshold disease (64 infants) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
<P>For both analyses, only small numbers of infants were involved and the trial lacked power to assess this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sepsis (Outcomes 2.9 and 3.9)</HEADING>
<P>There were no significant differences in the number of episodes of sepsis between the higher- and standard-dose groups (80 infants) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>) or between the once-a-week and standard regimens (80 infants) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin A concentration</HEADING>
<P>The data did not allow a quantitative analysis of vitamin A concentrations among survivors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>
<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> monitored for potential adverse effects. One infant in the higher-dose group was noted to have transient fullness of the anterior fontanelle without other causes and which resolved in 48 hours.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-08-16 10:08:06 -0400" MODIFIED_BY="[Empty name]">
<P>This Cochrane review includes 11 randomised controlled trials, ten comparing vitamin A with placebo and one comparing different vitamin A regimens. <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> is the largest trial included in the review with a sample size (807 infants) more than five times that of the next largest trial (154 infants, <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>).</P>
<P>The first version of this review reported a significant reduction in death or oxygen use at one month of age in vitamin A-treated infants (RR 0.75, 95% CI 0.62 to 0.91) (<LINK REF="REF-Darlow-1998" TYPE="REFERENCE">Darlow 1998</LINK>). The addition of <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>, which found no difference in outcome at one month, to the pooled data resulted in the meta-analysis showing only a trend of borderline significance towards reduction in death or oxygen use at this time (RR 0.93, 95% CI 0.86 to 1.00) (<LINK REF="REF-Darlow-2000" TYPE="REFERENCE">Darlow 2000</LINK>). <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>, the only trial to give supplemental vitamin A via the enteral route, had a moderate sample size (154) and found no significant benefit of supplementation; however, the further addition of data from this trial resulted in the meta-analysis showing a small but statistically significant reduction in this outcome (RR 0.93, 95% CI 0.88 to 0.99; RD &#8722;0.05, 95% CI &#8722;0.10 to &#8722;0.01; NNTB 20, 95% CI 10 to 100).</P>
<P>Four trials which gave intramuscular vitamin A to supplemented infants reported outcomes at 36 weeks' postmenstrual age (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>; <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; <LINK REF="STD-Mactier-2012" TYPE="STUDY">Mactier 2012</LINK>). The meta-analysis of these trials supports a marginal reduction in oxygen use in vitamin A-treated infants at 36 weeks' postmenstrual age (typical RR 0.89, 95% CI 0.78 to 1.00; typical RD &#8722;0.06, 95% CI &#8722;0.13 to 0.00; NNTB 16, 95% CI 8 to 1000+; 906 infants) as well as a marginal reduction in death or oxygen use at 36 weeks' postmenstrual age (typical RR 0.92, 95% CI 0.84 to 1.01; typical RD &#8722;0.05, 95% CI &#8722;0.11 to 0.01; 1089 infants). From the meta-analysis of the combined data, the NNTB with regard to oxygen requirement at 36 weeks is 13 with wide 95% confidence intervals, ranging from 7 to more than 1000. It is also noteworthy that there was no difference in other outcomes, including days of ventilation and length of stay, and between vitamin A-supplemented and control infants in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>.</P>
<P>Some differences between the trials may be explained by the differences in patient populations (birth weight and ethnicity), the differences in both the route of vitamin A supplementation (intramuscular, intravenous in lipid emulsion, or enteral), and the dose given. <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> and <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> included somewhat lower birth weight infants (401 to 1000 grams and &lt; 1000 grams respectively) than most other trials whereas other trials used various lower weight limits (500 grams for <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK>; 700 grams for <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> and <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK>; 725 grams for <LINK REF="STD-Werkman-1994" TYPE="STUDY">Werkman 1994</LINK>; and 1000 grams for <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>). The incidence of supplemental oxygen requirement at one month of age in vitamin A-supplemented infants was higher at 73% in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> and 83% in <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>, compared with a range of 34% to 67% in the other trials; this is consistent with their lower birth weight and gestational age. For the smallest infants the outcome at 36 weeks' postmenstrual age may be more clinically relevant.</P>
<P>In all the included trials there were higher vitamin A or retinol concentrations in the infants in the vitamin A group compared with the control group at most of the time periods studied. <LINK REF="REF-Kennedy-1997" TYPE="REFERENCE">Kennedy 1997</LINK> reported that an intramuscular dose of 5000 IU vitamin A three times per week was required to achieve serum concentrations greater than 250 &#956;g/L in most very low birth weight infants. This was the dose used by <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> and was generally greater than the dose used in earlier studies; for example, <LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK> used 4000 IU three times weekly, <LINK REF="STD-Papagaroufalis-1988" TYPE="STUDY">Papagaroufalis 1988</LINK> used 4000 IU on alternate days while the infants were ventilated, <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> and <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> used 2000 IU on alternate days, and <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> used between 1500 IU and 3000 IU for three doses only. Nevertheless, in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> 25% of infants who received supplemental vitamin A and 54% of controls (data from the first 300 enrolled infants) had vitamin A concentrations below 200 &#956;g/L on day 28. Similar percentages, 22% of those who received supplemental vitamin A and 45% of controls, had a relative dose response (change in the serum retinol concentration divided by the pre-injection concentration) of more than 10% following an intramuscular dose of 2000 IU. Taken together, these data suggest that an even higher dose of vitamin A given intramuscularly may be required to achieve vitamin A sufficiency in very premature infants.</P>
<P>In <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>, infants received a much higher cumulative dose of supplemental vitamin A than in other studies (140,000 IU in 28 days compared with 60,000 IU in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>) but by the enteral route. Vitamin A concentrations were only measured in the first 84 infants enrolled and the median concentration 24 hours after the first dose was significantly higher in supplemented infants (230 &#956;g/L versus 150 &#956;g/L). At 7 and 28 days of age, however, there were no significant differences in vitamin A concentrations between the groups and the median concentration in both groups was less than 200 &#956;g/L at these times. Vitamin A absorption is less efficient using the enteral route. <LINK REF="STD-Rush-1994" TYPE="STUDY">Rush 1994</LINK> compared the same dose of vitamin A (2000 IU/kg on alternate days) given by intramuscular injection or orally and reported that the former route gave higher plasma vitamin A concentrations after one week. <LINK REF="STD-Landman-1992" TYPE="STUDY">Landman 1992</LINK> reported that enteral supplementation with 5000 IU vitamin A daily resulted in similar plasma concentrations at 32 days of age to those resulting from 2000 IU vitamin A on alternate days by the intramuscular route.</P>
<P>There were also quite marked differences in the vitamin A dose received by the control groups. This has previously been suggested to account for differences in outcome between the early studies (<LINK REF="REF-Lorch-1994" TYPE="REFERENCE">Lorch 1994</LINK>). Infants in the control group in <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> received higher doses of vitamin A and had mean vitamin A concentrations at weeks three and four of greater than 200 &#956;g/L. This is higher than in infants in the control group in <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> in which mean vitamin A concentrations were less than 150 &#956;g/L at these times. One interpretation is that <LINK REF="STD-Shenai-1987" TYPE="STUDY">Shenai 1987</LINK> demonstrated a benefit of supplemental vitamin A in a population with vitamin deficiency, while <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> showed a minimal benefit of additional supplementation in a population with more adequate vitamin status. However, <LINK REF="REF-Georgieff-1989" TYPE="REFERENCE">Georgieff 1989</LINK> reported that postnatal steroids led to a near doubling of plasma vitamin A concentrations, and this finding was confirmed in <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>. Certainly variability in exposure to postnatal steroids complicates the interpretation of these data. Two trials included in this review reported the incidence of treatment with postnatal steroids (<LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK>, 46% in vitamin A group and 44% in controls; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK>, 39% and 34% respectively), while two others noted that steroids were used in some infants (<LINK REF="STD-Bental-1994" TYPE="STUDY">Bental 1994</LINK>; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>).</P>
<P>Further information on the optimal dosage of intramuscular vitamin A for infants with birth weights 401 to 1000 grams is available from the <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> trial. <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> compared the dose regimen used by <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> (5000 IU three times weekly for four weeks) with both a higher dose (10,000 IU three times weekly for four weeks) and a once-a-week dose (15,000 IU weekly for four weeks) in 120 infants. Only two infants received postnatal steroids between study days 21 and 28. Compared with the standard regimen, the higher dose regimen was not associated with a significantly higher mean retinol concentration at 28 days and there were no differences between the groups in the proportion of infants having concentrations of less than 200 &#956;g/L at this time (26% versus 21%). The once-a-day regimen, however, was associated with significantly lower mean concentrations at 28 days and increased the risk of infants having concentrations of less than 200 &#956;g/L at this time by a factor of 2.5 (26% versus 65%).</P>
<P>Many other variables will also affect the rate of chronic lung disease, which is known to vary considerably between centres. These factors include use of antenatal steroids (stated in four trials: <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> where they were received by 26% of study infants and 41% controls; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> where the rates were 76% and 74%; <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> where the rates were 77% and 82%; and <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> where the rates were 86% and 72%); exogenous surfactant (stated in three trials: <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> where &gt; 90% received an artificial surfactant; <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK> where &gt; 80% received a natural surfactant; and <LINK REF="STD-Wardle-2001" TYPE="STUDY">Wardle 2001</LINK> where all but one infant in the control group received an artificial surfactant); mode of ventilation including early nasal continuous positive airway pressure; postnatal steroids; and criteria for prescribing supplemental oxygen.</P>
<P>Despite the variations among trials discussed above, the quality assessment of the body of evidence found in this review for the critical neonatal outcomes was judged to be of moderate quality. The effect of vitamin A on 28-day outcomes (chronic lung disease or death, or both), death before 36 weeks' postmenstrual age, and chronic lung disease (oxygen use at 36 weeks' postmenstrual age in survivors) is of moderate quality; therefore the possibility exists that the true effect is different than that estimated here and further research could change the estimates of the effects on these last outcomes.</P>
<P>Less is known regarding follow-up at 18 to 24 months. <LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK> assessed 85% of infants who participated in the study of <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>. Results regarding the long-term effects that vitamin A could have on either neurodevelopment impairment (RR 0.89, 95% CI 0.74 to 1.08) or the combined outcome of death or neurodevelopmental impairment (RR 0.92, 95% CI 0.81 to 1.05) were inconclusive. The low quality of evidence for the neurodevelopment impairment makes evident the need for further research to define the long-term effects of the supplementation of vitamin A in preterms. This trial was not powered appropriately to assess long-term outcomes, and the benefit or harm from repeated intramuscular vitamin A following birth remains uncertain.</P>
<P>The studies did not generally report the frequency or severity of adverse events, although <LINK REF="STD-Pearson-1992" TYPE="STUDY">Pearson 1992</LINK> noted that repeat intramuscular injections may have been painful.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Supplementing very low birth weight infants with vitamin A is associated with a small benefit in terms of reducing death or oxygen use at one month of age and a marginal reduction in oxygen use at 36 weeks' postmenstrual age. Supplementation with vitamin A may also reduce the incidence of retinopathy of prematurity and of nosocomial sepsis. The trials do not allow judgement as to the best route of supplementation, although the one trial that gave enteral vitamin A found no significant benefit for supplementation. One trial compared different intramuscular dosing regimens and the results suggest that, at least for infants with birth weight 401 to 1000 grams, the optimal dose appears to be 5000 IU three times weekly for four weeks, although on this regimen 26% of infants still had plasma vitamin A concentrations below 200 &#956;g/L (0.70 &#956;mol/L), which may indicate deficiency (<LINK REF="STD-Ambalavanan-2003" TYPE="STUDY">Ambalavanan 2003</LINK>).</P>
<P>The conclusion of a marginal benefit at 36 weeks' postmenstrual age is derived from the results of five trials in which most infants had a birth weight less than 1000 grams. An earlier version of this Cochrane Review stated that whether clinicians decide to utilise repeat intramuscular doses of vitamin A may well depend upon the incidence of supplemental oxygen requirements at 36 weeks' postmenstrual age in extremely low birth weight infants in their unit; and their own assessment in conjunction with the review's findings of the benefits of a modest reduction in this outcome balanced against a lack of other proven benefits and the acceptability of the treatment (<LINK REF="REF-Darlow-2002" TYPE="REFERENCE">Darlow 2002</LINK>). Long-term follow-up data at 18 to 22 months' corrected age of the largest included trial has shown no evidence of either benefit or harm at this time (<LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>). If a decision has been made not to treat for the early benefits the follow-up study is unlikely to change that decision. On the other hand, if a decision has been made to treat for early benefits the follow-up study is reassuring in that long-term harmful effects are unlikely.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-08-02 17:19:29 -0400" MODIFIED_BY="[Empty name]">
<P>Further investigations are warranted as to the relationship between biochemical and functional vitamin A status in very low birth weight infants. Also, the benefits in terms of vitamin A status, clinical outcomes, safety, and acceptability to caretakers and parents of delivering vitamin A in an intravenous lipid emulsion from the first days of life, compared with delivery by intramuscular injections, should be investigated in a randomised controlled trial.</P>
<P>There is an epidemic of retinopathy of prematurity in middle-income and low-income countries that affects many infants who are more mature at birth and have a greater birth weight than most infants who acquire severe retinopathy in more developed countries. In many of these countries the vitamin A status of both mothers and infants is particularly poor. The trends towards less retinopathy of prematurity associated with supplemental vitamin A and higher-dose regimens seen in this review suggest that further trials should be undertaken in these countries to assess the possible contribution of poor perinatal vitamin A status to retinopathy of prematurity, and the need for intervention studies in these populations.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>We are grateful to Dr K Kennedy, University of Texas Southwestern Medical Center, Dallas, for supplying some original data and for helpful advice. We are also grateful to Drs Bengal, Wardle, Gelb (with regard to the <LINK REF="STD-Ravishankar-2003" TYPE="STUDY">Ravishankar 2003</LINK> trial), and Ambalavanan for supplying some original data for earlier versions of this Cochrane review.</P>
<P>Cochrane Neonatal has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C.</P>
<P>The 2010 update was completed centrally by Roger Soll of Cochrane Neonatal with the approval of the authors.</P>
<P>The authors thank the Cochrane Editorial Unit and the CNRG for the support in preparing the 'Risk of bias' tables and the 'Summary of findings' tables for the 2016 update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-07-11 12:19:24 -0400" MODIFIED_BY="[Empty name]">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-07-11 12:19:20 -0400" MODIFIED_BY="[Empty name]">
<P>The original review was conducted and written by Brian A Darlow and PJ Graham. The review update was facilitated by Roger Soll, Co-ordinating Editor of Cochrane Neonatal and Maria Ximena Rojas, Associate Editor of Cochrane Neonatal and approved by the original authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-08-16 10:33:22 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Differences in methods between protocol and review published in 1998</B>
</P>
<UL>
<LI>Addition of the outcome &#8216;retinopathy of prematurity&#8217;.</LI>
<LI>Dichotomous outcomes analysed via the relative risk, risk difference and number needed to treat (protocol only noted analysis using the risk difference).</LI>
<LI>Details about heterogeneity and the effect on the analysis (whether to pool and if so via fixed-effect or random-effects models); details of meta-regression if substantial heterogeneity; and information about subgroup analyses by infant size, deleted from the review.</LI>
</UL>
<P>
<B>Differences in methods between review published 1998 and review published 2000</B>
</P>
<UL>
<LI>Addition of the outcome &#8216;nosocomial infection&#8217;.</LI>
</UL>
<P>
<B>Differences in methods between review published 2000 and review published 2007</B>
</P>
<UL>
<LI>Addition of the comparison &#8216;Vitamin A supplementation comparing dosage regimes&#8217;.</LI>
<LI>Addition of the outcome &#8216;neurodevelopmental disability&#8217;.</LI>
</UL>
<P>
<B>Differences in methods between review published 2007 and review published 2011</B>
</P>
<UL>
<LI>Addition of the outcomes &#8216;Patent ductus arteriosus&#8217;, &#8216;Necrotizing enterocolitis&#8217;, &#8216;Intraventricular haemorrhage&#8217; and &#8216;Periventricular leukomalacia&#8217;.</LI>
<LI>Addition of searching clinical trials' registers.</LI>
<LI>Addition of 'Risk of bias' assessment of included studies using the methods of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>Addition of fixed-effect model for all meta-analyses.</LI>
<LI>Change from mean difference to standardised mean difference.</LI>
<LI>Addition of quality of the evidence assessment using the GRADE methodology. 'Summary of findings' tables added with outcomes: death before one month, oxygen use at one month in survivors, death before 36 weeks PMA, oxygen use at 36 weeks PMA in survivors, death before 18 to 22 months, neurodevelopmental impairment at 18 to 22 months, failure of ductal closure or treatment by day 14, one or more episodes of sepsis, necrotizing enterocolitis, intraventricular haemorrhage (IVH) - any IVH, retinopathy of prematurity (any grade).</LI>
<LI>Addition of subgroup analyses by route, dose, and timing of supplementation.</LI>
<LI>Addition of sensitivity analyses to assess the impact of risk of bias assessments.</LI>
</UL>
<P>
<B>Differences in methods between review published 2011 and review published 2016</B>
</P>
<UL>
<LI>Outcome changed from &#8216;Retinopathy of prematurity&#8217; to &#8216;Retinopathy of prematurity (any, or requiring laser therapy)&#8217;.</LI>
<LI>Addition of the composite outcome &#8216;death or chronic lung disease at 28 days and 36 weeks postmenstrual age&#8217; to the 'Summary of findings' table.</LI>
<LI>Deletion of the following outcomes from the 'Summary of findings' table: failure of ductal closure or treatment by day 14, one or more episodes of sepsis, necrotizing enterocolitis, intraventricular haemorrhage (IVH) - any IVH, retinopathy of prematurity (any grade).</LI>
<LI>Addition of detail about how quality of the evidence would be assessed.</LI>
</UL>
<P>
<B>Differences between methods stated and methods conducted</B>
</P>
<P>In &#8216;Methods &gt; Data collection and analysis &gt; Assessment of risk of bias of included studies&#8217;, the assessment of detection bias (blinding of outcome assessors) has not been mentioned, but in the risk of bias assessments detection bias has been combined with performance bias.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-11-14 06:29:06 -0500" MODIFIED_BY="[Empty name]">
<P>None</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-22 15:35:07 +0100" MODIFIED_BY="Colleen Ovelman">
<STUDIES MODIFIED="2016-08-02 19:24:44 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-07-20 11:51:05 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Ambalavanan-2003" MODIFIED="2010-07-22 05:12:01 -0400" MODIFIED_BY="[Empty name]" NAME="Ambalavanan 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-22 05:12:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA</AU>
<TI>A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>142</VL>
<NO>6</NO>
<PG>656-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090619"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090618"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bental-1994" MODIFIED="2010-07-22 05:15:11 -0400" MODIFIED_BY="[Empty name]" NAME="Bental 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-22 05:14:09 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;*Bental RY, Cooper PA, Cummins RR, et al. Vitamin A therapy - effects on the incidence of bronchopulmonary dysplasia. S Afr J Food Sci Nutr 1994; 6: 141-145.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:14:09 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bental RY, Cooper PA, Cummins RR, Sandler DL, Wainer S, Rotschild A</AU>
<TI>Vitamin A therapy - effects on the incidence of bronchopulmonary dysplasia</TI>
<SO>South African Journal of Food Science and Nutrition</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>4</NO>
<PG>141-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090621"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-22 05:15:11 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bental RY, Cooper PA, Sandler D, Wainer S. The effects of vitamin A therapy on the incidence of chronic lung disease in premature infants. Pediatr Res 1990; 25: 296A.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:15:11 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bental RY, Cooper PA, Sandler D, Wainer S</AU>
<TI>The effects of vitamin A therapy on the incidence of chronic lung disease in premature infants [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1990</YR>
<VL>25</VL>
<PG>296A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090622"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090620"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiatchoosakun-2014" MODIFIED="2016-07-20 11:46:56 -0400" MODIFIED_BY="[Empty name]" NAME="Kiatchoosakun 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-20 11:46:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiatchoosakun P, Jirapradittha J, Panthongviriyakul MC, Khampitak T, Yongvanit P, Boonsiri P</AU>
<TI>Vitamin A supplementation for prevention of bronchopulmonary dysplasia in very-low-birth-weight premature Thai infants: a randomized trial</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2014</YR>
<VL>97</VL>
<NO>Suppl 10</NO>
<PG>S82-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090624"/><IDENTIFIER TYPE="PUBMED" VALUE="25816542"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mactier-2012" MODIFIED="2014-11-14 06:48:58 -0500" MODIFIED_BY="[Empty name]" NAME="Mactier 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-14 06:48:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mactier H, McCulloch DL, Hamilton R, Galloway P, Bradnam MS, Young D, et al</AU>
<TI>Vitamin A supplementation improves retinal function in infants at risk of retinopathy of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>160</VL>
<NO>6</NO>
<PG>954-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090626"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-01 14:54:03 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090625"/><IDENTIFIER MODIFIED="2014-10-01 14:54:03 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jpeds.2011.12.013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Papagaroufalis-1988" MODIFIED="2010-07-22 05:16:23 -0400" MODIFIED_BY="[Empty name]" NAME="Papagaroufalis 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-07-22 05:16:23 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Papagaroufalis C, Cairis M, Pantazatou E, et al. A trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia (abstract). Pediatr Res 1988; 23: 518A.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:16:23 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papagaroufalis C, Cairis M, Pantazatou E, Meghreli Ch, Xanthou M</AU>
<TI>A trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1988</YR>
<VL>23</VL>
<PG>518A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090627"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearson-1992" MODIFIED="2014-06-15 08:51:17 -0400" MODIFIED_BY="Heather Maxwell" NAME="Pearson 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-06-15 08:51:17 -0400" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Pearson E, Bose C, Snidow, T, et al. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992; 121: 420-427.&lt;/p&gt;" NOTES_MODIFIED="2014-06-15 08:51:17 -0400" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearson E, Bose C, Snidow T, Ransom L, Young T, Bose G, et al</AU>
<TI>Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>121</VL>
<NO>3</NO>
<PG>420-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090629"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ravishankar-2003" MODIFIED="2010-07-22 05:19:10 -0400" MODIFIED_BY="[Empty name]" NAME="Ravishankar 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-22 05:17:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nafday S, Ravishankar C, Green RS, Kamenir SA, Lorber R, Stacewicz-Sapuntzakis M, et al</AU>
<TI>A trial of vitamin A therapy to facilitate ductal closure in premature infants [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>308A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-22 05:19:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ravishankar C, Nafday S, Green RS, Kamenir S, Lorber R, Stacewicz-Sapuntzakis M, et al</AU>
<TI>A trial of vitamin A therapy to facilitate ductal closure in premature infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>5</NO>
<PG>644-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090631"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shenai-1987" MODIFIED="2010-07-22 05:19:43 -0400" MODIFIED_BY="[Empty name]" NAME="Shenai 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-07-22 05:19:43 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Shenai JP, Kennedy KA, Chytil F, et al. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987; 111: 269-177.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:19:43 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shenai JP, Kennedy KA, Chytil F, Stahlman MT</AU>
<TI>Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1987</YR>
<VL>111</VL>
<NO>2</NO>
<PG>269-77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyson-1999" MODIFIED="2016-07-20 11:51:05 -0400" MODIFIED_BY="[Empty name]" NAME="Tyson 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-07-20 11:49:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, et al; National Institute of Child Health and Human Development Neonatal Research Network</AU>
<TI>Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>3</NO>
<PG>e249-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090637"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-20 11:51:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network</AU>
<TI>Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants</TI>
<SO>American Journal of Perinatology</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>9</NO>
<PG>771-80</PG>
<IDENTIFIERS MODIFIED="2015-07-13 10:24:38 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090638"/><IDENTIFIER MODIFIED="2015-07-13 10:24:38 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1055/s-0032-1333410"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-22 05:22:11 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tyson JE, Ehrenkranz RA, Stoll BJ, et al. Vitamin (Vit) A supplementation to increase survival without chronic lung disease (CLD) in extremely low birth weight (ELBW) infants: a 14-center randomized trial (abstract). Pediatr Res 1998; 43: 199A.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:22:11 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyson JE, Ehrenkranz RA, Stoll BJ, Wright LL, Mele L, Kennedy KA, et al</AU>
<TI>Vitamin (Vit) A supplementation to increase survival without chronic lung disease (CLD) in extremely low birth weight (ELBW) infants: a 14-center randomized trial [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>199A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090639"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-22 05:23:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;*Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med 1999; 340: 1962-1968.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:23:35 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al</AU>
<TI>Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>25</NO>
<PG>1962-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090640"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wardle-2001" MODIFIED="2014-11-14 06:51:29 -0500" MODIFIED_BY="[Empty name]" NAME="Wardle 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wardle SP, Hughes A, Chen S, Shaw NJ</AU>
<TI>Randomised controlled trial of oral vitamin A supplementation to prevent chronic lung disease [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>914</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090642"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-14 06:51:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wardle SP, Hughes A, Chen S, Shaw NJ</AU>
<TI>Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease</TI>
<SO>Archives of Disease in Childhood Fetal and Neonatal Edition</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>1</NO>
<PG>F9-F13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090643"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090641"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Werkman-1994" MODIFIED="2010-07-22 05:24:45 -0400" MODIFIED_BY="[Empty name]" NAME="Werkman 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-22 05:24:45 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Werkman SH, Peeples JM, Cooke RJ, et al. Effect of vitamin A supplementation of intravenous lipids on early vitamin A intake and status of premature infants. Am J Clin Nutr 1994; 59:586-592&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 05:24:45 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Werkman SH, Peeples JM, Cooke RJ, Tolley EA, Carlson SE</AU>
<TI>Effect of vitamin A supplementation of intravenous lipids on early vitamin A intake and status of premature infants</TI>
<SO>American Journal of Clinical Nutriton</SO>
<YR>1994</YR>
<VL>59</VL>
<NO>3</NO>
<PG>586-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090645"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090644"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-20 11:57:06 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Aranda-1992" MODIFIED="2014-09-12 13:10:38 -0400" MODIFIED_BY="[Empty name]" NAME="Aranda 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-09-12 13:10:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Aranda JV, Akramoff L, Beharry E, et al. Plasma concentrations of vitamin A and E during supplemental therapy in premature infants (abstract). Pediatr Res 1992; 31: 57A.&lt;/p&gt;" NOTES_MODIFIED="2014-09-12 13:10:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aranda JV, Akramoff L, Beharry K, Ling E, Papageorgiou A</AU>
<TI>Plasma concentrations of vitamin A and E during supplemental therapy in premature infants [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>57A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090647"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aurvag-2007" MODIFIED="2010-07-22 06:45:52 -0400" MODIFIED_BY="[Empty name]" NAME="Aurvag 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-22 06:45:52 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aurvåg AK, Henriksen C, Drevon CA, Iversen PO, Nakstad B</AU>
<TI>Improved vitamin A supplementation regimen for breastfed very low birth weight infant</TI>
<SO>Acta Pædiatrica</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>9</NO>
<PG>1296-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090649"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-14 21:30:38 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090648"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coutsoudis-1996" MODIFIED="2016-07-20 11:52:34 -0400" MODIFIED_BY="[Empty name]" NAME="Coutsoudis 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-07-20 11:52:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coutsoudis A, Adhikari M, Pillay K, Coovadia HM</AU>
<TI>Absorption of high-dose enteral vitamin A in low-birth-weight neonates</TI>
<SO>South African Medical Journal</SO>
<YR>1996</YR>
<VL>86</VL>
<NO>10 Suppl</NO>
<PG>1337-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4357106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coutsoudis-2000" MODIFIED="2010-07-22 06:46:30 -0400" MODIFIED_BY="[Empty name]" NAME="Coutsoudis 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-07-22 06:46:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coutsoudis A, Adhikari M, Pillay K, Kuhn L, Coovadia HM</AU>
<TI>Effect of vitamin A supplementation on morbidity of low-birth-weight neonates</TI>
<SO>South African Medical Journal</SO>
<YR>2000</YR>
<VL>90</VL>
<NO>7</NO>
<PG>730-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090651"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090650"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Koo-1993" MODIFIED="2016-07-20 11:55:50 -0400" MODIFIED_BY="[Empty name]" NAME="Koo 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-07-20 11:53:18 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Koo W, Krug-Wispe S, Tsang R. Effect of differential enteral vitamin A intakes in very low birth weight infants (abstract). Pediatr Res 1993; 33:306A.&lt;/p&gt;" NOTES_MODIFIED="2016-07-20 11:53:18 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koo W, Krug-Wispe S, Tsang R</AU>
<TI>Effect of differential enteral vitamin A intakes in very low birth weight infants [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>306A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090653"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-20 11:55:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koo WW, Krug-Wispe S, Succop P, Tsang RC, Neylan M</AU>
<TI>Effect of different vitamin A intakes on very-low-birth-weight infants</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1216-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357108"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090652"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landman-1992" MODIFIED="2010-07-22 06:47:45 -0400" MODIFIED_BY="[Empty name]" NAME="Landman 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-07-22 06:47:45 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Landman J, Sive A, Hesse De V, et al. Comparison of enteral and intramuscular vitamin A supplementation in preterm infants. Early Human Dev 1992; 30: 163-170.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 06:47:45 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landman J, Sive A, Heese HD, Van der Elst C, Sacks R</AU>
<TI>Comparison of enteral and intramuscular vitamin A supplementation in preterm infants</TI>
<SO>Early Human Development</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>2</NO>
<PG>163-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090655"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090654"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longardt-2014" MODIFIED="2016-07-20 11:56:32 -0400" MODIFIED_BY="[Empty name]" NAME="Longardt 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-20 11:56:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longardt AC, Schmiedchen B, Raila J, Schweigert FJ, Obladen M, Bührer C, et al</AU>
<TI>Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2014</YR>
<VL>68</VL>
<NO>12</NO>
<PG>1300-4</PG>
<IDENTIFIERS MODIFIED="2016-07-18 18:29:31 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357110"/><IDENTIFIER MODIFIED="2016-07-18 18:29:31 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25315494"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-07-18 18:27:19 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4357109"/><IDENTIFIER MODIFIED="2016-07-18 18:27:19 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1038/ejcn.2014.202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robbins-1993" MODIFIED="2010-07-22 06:48:10 -0400" MODIFIED_BY="[Empty name]" NAME="Robbins 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-07-22 06:48:10 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Robbins ST, Fletcher AB. Early vs delayed vitamin A supplementation in very-low-birth-weight infants. JPEN 1993; 17: 220-225.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 06:48:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robbins ST, Fletcher AB</AU>
<TI>Early vs delayed vitamin A supplementation in very-low-birth-weight infants</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>3</NO>
<PG>220-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090657"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090656"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rush-1994" MODIFIED="2010-07-22 06:48:38 -0400" MODIFIED_BY="[Empty name]" NAME="Rush 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-22 06:48:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rush MG, Shenai JP, Parker RA, et al. Intramuscular versus enteral vitamin A supplementation in very low birth weight neonates. J Pediatr 1994; 125: 458-462.&lt;/p&gt;" NOTES_MODIFIED="2010-07-22 06:48:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rush MG, Shenai JP, Parker RA, Chytil F</AU>
<TI>Intramuscular versus enteral vitamin A supplementation in very low birth weight neonates</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>125</VL>
<NO>3</NO>
<PG>458-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090659"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090658"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmiedchen-2016" MODIFIED="2016-07-20 11:57:06 -0400" MODIFIED_BY="[Empty name]" NAME="Schmiedchen 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-07-20 11:57:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmiedchen B, Longardt AC, Loui A, Bührer C, Raila J, Schweigert FJ</AU>
<TI>Effect of vitamin A supplementation on the urinary retinol excretion in very low birth weight infants</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2016</YR>
<VL>175</VL>
<NO>3</NO>
<PG>365-72</PG>
<IDENTIFIERS MODIFIED="2016-07-18 18:12:41 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357112"/><IDENTIFIER MODIFIED="2016-07-18 18:12:41 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 26475348"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-07-18 18:11:14 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4357111"/><IDENTIFIER MODIFIED="2016-07-18 18:11:14 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s00431-015-2647-9"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-08-02 19:24:44 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Calisici--2014" MODIFIED="2016-08-02 19:24:44 -0400" MODIFIED_BY="[Empty name]" NAME="Calisici  2014" YEAR="2014">
<REFERENCE MODIFIED="2016-08-02 19:24:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calisici E, Yarci E, Degirmencioglu H, Oncel MY, Oguz SS, Uras N, et al</AU>
<TI>PO-0731 The effects of early oral vitamin a treatment on the prevention of bronchopulmonary dysplasia in the low birth weight infants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2014</YR>
<VL>99</VL>
<NO>Suppl 2</NO>
<PG>A494</PG>
<IDENTIFIERS MODIFIED="2016-07-19 11:12:52 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090661"/><IDENTIFIER MODIFIED="2016-07-19 11:12:52 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/archdischild-2014-307384.1371"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-01 17:41:59 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090660"/><IDENTIFIER MODIFIED="2015-06-01 17:41:59 -0400" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="AN: 71667613 "/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-07-20 12:53:31 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2013" MODIFIED="2016-07-20 12:53:31 -0400" MODIFIED_BY="[Empty name]" NAME="Meyer 2013" YEAR="2014">
<REFERENCE MODIFIED="2016-07-20 12:12:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer S, Gortner L, Monz D, Maurer E, Nohr D, Biesalski HK; NeoVitaA Study Group</AU>
<TI>Vitamin A administration using nasogastric tubes</TI>
<SO>Early Human Development</SO>
<YR>2014</YR>
<VL>90</VL>
<NO>10</NO>
<PG>625-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357113"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-15 09:04:47 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer S, Gortner L, NeoVitaA Trial Investigators</AU>
<TI>Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants</TI>
<SO>Neonatology</SO>
<YR>2014</YR>
<VL>105</VL>
<NO>3</NO>
<PG>182-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090663"/><IDENTIFIER TYPE="PUBMED" VALUE="24434948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-20 12:53:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyer S, Kronfeld K, Gräber S, Butzer R, Wahl H, Gortner L</AU>
<TI>Vitamin A to prevent bronchopulmonary dysplasia: the NeoVitaA trial</TI>
<SO>Journal of Maternal-fetal &amp; Neonatal Medicine</SO>
<YR>2013</YR>
<VL>26</VL>
<NO>5</NO>
<PG>544-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4357114"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090662"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-20 13:03:51 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-20 13:03:22 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bates-1995" MODIFIED="2010-07-22 06:49:36 -0400" MODIFIED_BY="[Empty name]" NAME="Bates 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bates CJ</AU>
<TI>Vitamin A</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<NO>8941</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chabra-1994" MODIFIED="2010-07-22 06:50:01 -0400" MODIFIED_BY="[Empty name]" NAME="Chabra 1994" TYPE="JOURNAL_ARTICLE">
<AU>Chabra S, Arnold JD, Leslie GI, Bowen JR, Earl J, Wood F</AU>
<TI>Vitamin A status in preterm neonates with and without chronic lung disease</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>5</NO>
<PG>432-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chytil-1992" MODIFIED="2010-07-22 06:50:54 -0400" MODIFIED_BY="[Empty name]" NAME="Chytil 1992" TYPE="JOURNAL_ARTICLE">
<AU>Chytil F</AU>
<TI>The lungs and vitamin A</TI>
<SO>American Journal of Physiology</SO>
<YR>1992</YR>
<VL>262</VL>
<NO>5 Pt 1</NO>
<PG>L517-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Georgieff-1989" MODIFIED="2010-07-22 06:51:32 -0400" MODIFIED_BY="[Empty name]" NAME="Georgieff 1989" TYPE="JOURNAL_ARTICLE">
<AU>Georgieff MK, Mammel MC, Mills MM, Gunter EW, Johnson DE, Thompson TR</AU>
<TI>Effect of postnatal steroid administration on serum vitamin A concentrations in newborn infants with respiratory compromise</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>114</VL>
<NO>2</NO>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro_x002d_GDT-2013" MODIFIED="2016-07-20 12:54:44 -0400" MODIFIED_BY="[Empty name]" NAME="GRADEpro-GDT 2013" TYPE="COMPUTER_PROGRAM">
<AU>Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group</AU>
<TI>GRADEpro-GDT</TI>
<YR>2013</YR>
<PB>GRADE working group</PB>
<MD>Avialable at:http://www.guidelinedevelopment.org/</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greene-1987" MODIFIED="2010-07-22 06:52:22 -0400" MODIFIED_BY="[Empty name]" NAME="Greene 1987" TYPE="JOURNAL_ARTICLE">
<AU>Greene HL, Phillips BL, Franck L, Fillmore CM, Said HM, Murrell JE, et al</AU>
<TI>Persistently low retinol levels during and after parenteral feeding of very low birthweight infants; examination of losses into intravenous administration sets and a method of prevention by addition to a lipid emulsion</TI>
<SO>Pediatrics</SO>
<YR>1987</YR>
<VL>79</VL>
<NO>6</NO>
<PG>894-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-07-20 12:56:18 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org,</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huiming-2005" MODIFIED="2010-07-22 06:52:35 -0400" MODIFIED_BY="[Empty name]" NAME="Huiming 2005" TYPE="COCHRANE_REVIEW">
<AU>Huiming Y, Chaomin W, Meng M</AU>
<TI>Vitamin A for treating measles in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-06-12 09:55:10 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-06-12 09:55:10 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001479.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Humphrey-1996" MODIFIED="2010-07-22 06:53:21 -0400" MODIFIED_BY="[Empty name]" NAME="Humphrey 1996" TYPE="JOURNAL_ARTICLE">
<AU>Humphrey JH, Agoestina T, Wu L, Usman A, Nurachim M, Subardja D, et al</AU>
<TI>Impact of neonatal vitamin A supplementation on infant morbidity and mortality</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>128</VL>
<NO>4</NO>
<PG>489-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hustead-1984" MODIFIED="2010-07-22 06:54:07 -0400" MODIFIED_BY="[Empty name]" NAME="Hustead 1984" TYPE="JOURNAL_ARTICLE">
<AU>Hustead VA, Gutcher GR, Anderson SA, Zachman RD</AU>
<TI>Relationship of vitamin A (retinol) status to lung disease in the preterm infant</TI>
<SO>Journal of Pediatrics</SO>
<YR>1984</YR>
<VL>104</VL>
<NO>4</NO>
<PG>610-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-1997" MODIFIED="2010-07-22 06:57:21 -0400" MODIFIED_BY="[Empty name]" NAME="Kennedy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy KA, Stoll BJ, Ehrenkranz RA, Oh W, Wright LL, Stevenson DK, et al</AU>
<TI>Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low? The NICHD Neonatal Research Network</TI>
<SO>Early Human Development</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>1</NO>
<PG>19-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorch-1994" MODIFIED="2010-07-22 06:57:58 -0400" MODIFIED_BY="[Empty name]" NAME="Lorch 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lorch V, Gaylord MS</AU>
<TI>Vitamin A and bronchopulmonary dysplasia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>2</NO>
<PG>328-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mactier-2005" MODIFIED="2014-11-14 06:55:00 -0500" MODIFIED_BY="[Empty name]" NAME="Mactier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mactier H, Weaver LT</AU>
<TI>Vitamin A and preterm infants: what we know, what we don't know, and what we need to know</TI>
<SO>Archives of Disease in Childhood Fetal and Neonatal Edition</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>2</NO>
<PG>F103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papile-1978" MODIFIED="2016-07-11 12:12:59 -0400" MODIFIED_BY="[Empty name]" NAME="Papile 1978" TYPE="JOURNAL_ARTICLE">
<AU>Papile LA, Burstein J, Burstein R, Koffler H</AU>
<TI>Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<NO>4</NO>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2010-07-21 06:08:24 -0400" MODIFIED_BY="[Empty name]" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2016-07-20 13:03:22 -0400" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; The GRADE Working Group</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendations [Updated October 2013]</TI>
<SO>Available from www.guidelinedevelopment.org/handbook</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shenai-1985" MODIFIED="2010-07-22 07:00:00 -0400" MODIFIED_BY="[Empty name]" NAME="Shenai 1985" TYPE="JOURNAL_ARTICLE">
<AU>Shenai JP, Chytil F, Stahlman MT</AU>
<TI>Vitamin A status of neonates with bronchopulmonary dysplasia</TI>
<SO>Pediatric Research</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>2</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shenai-1990" MODIFIED="2010-07-22 07:06:09 -0400" MODIFIED_BY="[Empty name]" NAME="Shenai 1990" TYPE="JOURNAL_ARTICLE">
<AU>Shenai JP, Rush MG, Stahlman MT, Chytil F</AU>
<TI>Plasma retinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>116</VL>
<NO>4</NO>
<PG>607-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shenai-1993" MODIFIED="2010-07-22 07:06:24 -0400" MODIFIED_BY="[Empty name]" NAME="Shenai 1993" TYPE="BOOK_SECTION">
<AU>Shenai JP</AU>
<TI>Vitamin A</TI>
<SO>Nutritional Needs of the Preterm Infant: Scientific Basis and Practical Guidelines</SO>
<YR>1993</YR>
<PG>87-100</PG>
<ED>Tsang RC, Lucas A, Uauy R, Zlotkin S</ED>
<PB>Williams and Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spears-2004" MODIFIED="2010-07-22 07:06:48 -0400" MODIFIED_BY="[Empty name]" NAME="Spears 2004" TYPE="JOURNAL_ARTICLE">
<AU>Spears K, Cheney C, Zerzan J</AU>
<TI>Low plasma retinol concentrations increase the risk of developing bronchopulmonary dysplasia and long-term respiratory disability in very-low-birth-weight infants</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>80</VL>
<NO>6</NO>
<PG>1589-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zachman-1996" MODIFIED="2010-07-22 07:38:35 -0400" MODIFIED_BY="[Empty name]" NAME="Zachman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Zachman RD, Samuels DP, Brand JM, Winston JF, Pi JT</AU>
<TI>Use of the intramuscular relative-dose-response test to predict bronchopulmonary dysplasia in premature infants</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1996</YR>
<VL>63</VL>
<NO>1</NO>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-07-20 13:03:51 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Darlow-1998" MODIFIED="2010-07-22 07:38:55 -0400" MODIFIED_BY="[Empty name]" NAME="Darlow 1998" TYPE="COCHRANE_REVIEW">
<AU>Darlow BA, Graham PJ</AU>
<TI>Vitamin A supplementation in very low birthweight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-06-12 09:58:09 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-06-12 09:58:09 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Darlow-2000" MODIFIED="2008-06-12 09:56:41 -0400" MODIFIED_BY="[Empty name]" NAME="Darlow 2000" TYPE="COCHRANE_REVIEW">
<AU>Darlow BA, Graham PJ</AU>
<TI>Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-06-12 09:56:41 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-06-12 09:56:41 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Darlow-2002" MODIFIED="2008-06-12 09:56:03 -0400" MODIFIED_BY="[Empty name]" NAME="Darlow 2002" TYPE="COCHRANE_REVIEW">
<AU>Darlow BA, Graham PJ</AU>
<TI>Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-06-12 09:56:03 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-06-12 09:56:03 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Darlow-2007" MODIFIED="2014-06-15 09:10:26 -0400" MODIFIED_BY="Heather Maxwell" NAME="Darlow 2007" TYPE="COCHRANE_REVIEW">
<AU>Darlow BA, Graham PJ</AU>
<TI>Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-06-17 15:30:27 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-06-17 15:30:27 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000501.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Darlow-2011" MODIFIED="2016-07-20 13:03:51 -0400" MODIFIED_BY="[Empty name]" NAME="Darlow 2011" TYPE="COCHRANE_REVIEW">
<AU>Darlow BA, Graham PJ</AU>
<TI>Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-06-15 09:09:14 -0400" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2014-06-15 09:09:14 -0400" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD000501.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-08-16 10:35:21 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-08-16 10:35:21 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ambalavanan-2003">
<CHAR_METHODS MODIFIED="2016-07-18 18:16:45 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:57:26 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 120</P>
<P>Description: birth weight between 401 and 1000 grams; requiring mechanical ventilation or supplemental oxygen at 24 hours of age; and no major congenital anomalies, non-bacterial infection, or terminal illness<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Comparison of vitamin A (water-soluble retinyl palmitate) regimens</P>
<OL>
<LI>Standard vitamin A regimen: 5000 IU vitamin A intramuscular injection 3 times a week for 4 weeks) (n = 40)</LI>
<LI>High dose vitamin A regimen: 10,000 IU vitamin A intramuscular injection 3 times a week for 4 weeks) (n = 40)</LI>
<LI>Once-per-week vitamin A regimen: 15,000 IU vitamin A intramuscular injection weekly for 4 weeks) (n = 40)</LI>
</OL>
<P>Other: 2 infants received postnatal steroids between study days 21 and 28</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-04 14:10:55 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Median retinol concentrations on day 28</LI>
<LI>Percentage of each group with retinol concentrations &lt; 200 &#956;g/L</LI>
<LI>Death before 36 weeks' postmenstrual age</LI>
<LI>Oxygen requirement at, or death before, 36 weeks' postmenstrual age</LI>
<LI>Threshold retinopathy of prematurity</LI>
<LI>Examination for potential toxicity at least 3 times weekly</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-29 14:38:43 -0400" MODIFIED_BY="[Empty name]">
<P>Location: University of Alabama at Birmingham (UAB), USA</P>
<P>Trial author provided further information on the timing of death, numbers of infants having serum retinol estimations at 28 days, and any retinopathy of prematurity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bental-1994">
<CHAR_METHODS MODIFIED="2016-07-18 18:16:56 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:57:33 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 60</P>
<P>Description: birth weight between 1000 and 1500 grams; gestational age of &#8804; 34 weeks; infants were receiving supplemental oxygen and mechanical ventilation for at least 72 hours during the first week; no congenital anomalies or infection; black South African infants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-soluble retinyl palmitate) vs control</P>
<OL>
<LI>Supplemental 4000 IU vitamin A intramuscular injection 3 times a week from day 4 for a total of 12 injections (n = 31)</LI>
<LI>No supplementation (n = 29)</LI>
</OL>
<P>Other: Some control and study infants received vitamin A 1500 to 3000 IU after 1 week of age when fed orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser">
<UL>
<LI>Death before 31 days</LI>
<LI>Bronchopulmonary dysplasia (oxygen or ventilation on day 31 and characteristic chest x-ray; full data obtained from trial authors)</LI>
<LI>Culture-proven sepsis</LI>
<LI>Vitamin A levels at various times</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-02 04:13:21 -0400" MODIFIED_BY="[Empty name]">
<P>Location: Baragwanath Hospital, Soweto, South Africa</P>
<P>Complete data published in an earlier abstract from 1990; we sought and obtained further clarification from the trial authors concerning 2 outcomes: oxygen use at 1 month in survivors; and death or oxygen use at 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 17:42:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiatchoosakun-2014">
<CHAR_METHODS MODIFIED="2016-07-26 09:00:16 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial to assess the effect of vitamin A supplementation for prevention of bronchopulmonary dysplasia in VLBW premature infants.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-08-02 17:42:26 -0400" MODIFIED_BY="[Empty name]">
<P>Eighty premature infants weighing &lt; 1500 grams who received mechanical ventilation or oxygen supplementation at 24 hours of age, admitted to Neonatal Units of Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-02 17:31:48 -0500" MODIFIED_BY="[Empty name]">
<P>Infants were assigned to receive either intramuscular vitamin A 5000 IU 3 times/week (treatment group) or sham procedure (control group) for four weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-02 17:42:50 -0400" MODIFIED_BY="[Empty name]">
<P>The investigators reported on serum vitamin A levels, and complications of prematurity including supplemental oxygen at 36 weeks' postmenstrual age, duration of intubation, days on oxygen therapy, and length of hospital stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-07 12:19:00 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-16 10:35:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mactier-2012">
<CHAR_METHODS MODIFIED="2016-07-18 18:17:23 -0400" MODIFIED_BY="[Empty name]">
<P>double-blind, randomised controlled trial conducted at three neonatal centres in Glasgow</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-08-16 10:35:21 -0400" MODIFIED_BY="[Empty name]">
<P>Number: 89 infants (42 supplemented and 47 controls)</P>
<P>Description: infants &lt; 32 weeks' gestation or &lt; 1501 grams birth weight, or both</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-14 06:33:20 -0500" MODIFIED_BY="[Empty name]">
<P>Supplemented infants received additional intramuscular vitamin A 10,000 IU 3 times weekly from day 2 for a minimum of 2 weeks or until establishment of oral feeding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-14 06:33:31 -0500" MODIFIED_BY="[Empty name]">
<P>Hepatic stores were assessed by relative dose response (RDR). The primary outcome measure was cone-corrected dark-adapted retinal rod sensitivity measured by electroretinogram at 36 weeks' postmenstrual age (PMA). Complications of prematurity were reported including use of respiratory support, intraventricular haemorrhage, retinopathy of prematurity, supplemental oxygen at 36 weeks postmenstrual age and death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-01 16:03:43 -0400" MODIFIED_BY="[Empty name]">
<P>www.ClinicalTrials.gov NCT004174404</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Papagaroufalis-1988">
<CHAR_METHODS MODIFIED="2016-07-18 18:17:42 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:57:47 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 55</P>
<P>Description: birth weight &#8804; 1300 grams; gestation &lt; 29 weeks; requirement for &gt; 40% oxygen and mechanical ventilation for &gt; 72 hours in first week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-soluble retinyl palmitate) vs control</P>
<OL>
<LI>Supplemental 4000 IU vitamin A intramuscular injection from day 4 to 6 on alternate days until extubated (n = 27)</LI>
<LI>Normal saline placebo (n = 28)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser">
<UL>
<LI>Death before 31 days</LI>
<LI>Bronchopulmonary dysplasia (oxygen requirement and characteristic chest x-ray on day 31)</LI>
</UL>
<P>Vitamin A levels at various times</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-29 14:38:03 -0400" MODIFIED_BY="[Empty name]">
<P>Location: not stated; possibly Aghia Sophia Children's Hospital and Institute of Child Health, Athens, Greece (authors' affiliation)</P>
<P>Amount of vitamin A in unsupplemented infants not stated</P>
<P>Trial author provided Dr K Kennedy with additional data at the time of an earlier review (<LINK REF="REF-Kennedy-1997" TYPE="REFERENCE">Kennedy 1997</LINK>), and these data are included in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearson-1992">
<CHAR_METHODS MODIFIED="2016-07-18 18:17:51 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:57:53 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 49</P>
<P>Description: birth weight 700 to 1100 grams; requiring supplemental oxygen and mechanical ventilation between 72 and 96 hours of age with previous cumulative duration of ventilation and oxygen &gt; 48 hours; no growth retardation (undefined), congenital, or chromosomal abnormalities, hydrops fetalis, congenital infection, neonatal hepatitis or 'do not resuscitate' order</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-soluble retinyl palmitate) versus control</P>
<OL>
<LI>Supplemental 2000 IU vitamin A by intramuscular injection alternate days from day 4 for 14 doses (n = 27)</LI>
<LI>Normal saline placebo or mock injection (n = 22)</LI>
</OL>
<P>Other: both control and study infants received 1200 to 1500 IU/d vitamin A in protein-dextrose solution when on parenteral nutrition; when fed orally all infants received vitamin A 250 to 1030 IU/100 mL milk; antenatal steroids received by 26% infants in the vitamin A group and 41% in the control group; &gt; 90% received an artificial surfactant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-02 17:47:41 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death before 31 days</LI>
<LI>Bronchopulmonary dysplasia (oxygen requirement at 31 days and characteristic chest x-ray)</LI>
<LI>Oxygen requirement at 34 weeks' post-conceptual age</LI>
<LI>Retinopathy of prematurity</LI>
<LI>Plasma vitamin A levels and retinyl binding protein at various times</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-19 04:00:52 -0400" MODIFIED_BY="Karla Soares-Weiser">
<P>Location: hospitals in North Carolina, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-18 18:18:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ravishankar-2003">
<CHAR_METHODS MODIFIED="2016-07-18 18:18:07 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:58:17 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 40</P>
<P>Description: birth weight 500 to 1500 grams; gestation &lt; 32 weeks; having indwelling umbilical line; no major congenital malformations or chromosomal anomalies; and &lt; 24 hours of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-14 06:36:57 -0500" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-miscible preparation of vitamin A (Aquasol A)) versus control</P>
<OL>
<LI>Supplemental 1500 to 3000 IU vitamin A (based on weight) by intramuscular injection on days 1, 3, and 7 (n = 22)</LI>
<LI>Sham injection (n = 18)</LI>
</OL>
<P>Other: most infants received parenteral nutrition including 466 IU/dL vitamin A and an additional 1000 IU supplement when fed orally; antenatal steroids received by 86% of infants in the vitamin A group and 72% in the control group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-02 04:14:15 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Failure of patent ductus arteriosus closure, defined as patent ductus arteriosus larger than trivial on day 14, indomethacin treatment, or surgical ligation</LI>
<LI>Death</LI>
<LI>Bronchopulmonary dysplasia (oxygen requirement at 36 weeks' postmenstrual age)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-29 14:39:49 -0400" MODIFIED_BY="[Empty name]">
<P>Location: Mount Sinai Medical Center, New York, New York, USA</P>
<P>Patent ductus arteriosus closure primary outcome</P>
<P>Corresponding author provided information on the age at death for infants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shenai-1987">
<CHAR_METHODS MODIFIED="2016-07-18 18:18:21 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-02 10:58:29 -0500" MODIFIED_BY="[Empty name]">
<P>Number: 40</P>
<P>Description: birth weight 700 to 1300 grams; gestation 26 to 30 week; requiring supplemental oxygen and mechanical ventilation for at least 72 hours in the first week; Caucasian infants only; birth weight appropriate for gestational age; no congenital abnormalities</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-soluble retinyl palmitate) versus control</P>
<OL>
<LI>Supplemental 2000 IU vitamin A by intramuscular injection alternate days from day 4 for a total of 14 injections (n = 20)</LI>
<LI>Normal saline placebo (n = 20)</LI>
</OL>
<P>Other: both control and study infants received vitamin A 400 IU/dL in parenteral nutrition and 240 to 550 IU/dL from milk plus 1500 IU supplements when fed orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-19 04:00:54 -0400" MODIFIED_BY="Karla Soares-Weiser">
<UL>
<LI>Death before 31 days</LI>
<LI>Bronchopulmonary dysplasia (oxygen requirement or ventilation at 31 days plus characteristic chest x-ray)</LI>
<LI>Total days oxygen</LI>
<LI>Episodes of sepsis</LI>
<LI>Retinopathy of prematurity</LI>
<LI>Vitamin A levels at various times</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-19 04:00:54 -0400" MODIFIED_BY="Karla Soares-Weiser">
<P>Location: Vanderbilt Medical Centre, Nashville, Tennessee, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-16 10:28:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tyson-1999">
<CHAR_METHODS MODIFIED="2016-07-18 18:18:35 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-31 14:42:40 -0400" MODIFIED_BY="[Empty name]">
<P>Number: 807</P>
<P>Description: birth weight 401 to 1000 grams; requiring supplemental oxygen or mechanical ventilation at 24 hours of age; and no major congenital anomalies, non-bacterial infection, or terminal illness</P>
<P>Conducted at hospitals in the NICHD Neonatal Network (USA)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (water-soluble retinyl palmitate) versus control</P>
<OL>
<LI>Supplemental 5000 IU vitamin A intramuscular injection 3 times a week for 4 weeks (n = 405)</LI>
<LI>Sham injection (n = 402)</LI>
</OL>
<P>Other: control and study infants received similar intakes of vitamin A from non-study enteral and parenteral sources but amounts not stated; antenatal steroids received by 76% of infants in the vitamin A group and 74% in the control group; &gt; 80% received a natural surfactant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-16 10:28:42 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Oxygen requirement at, or death before, 36 weeks' postmenstrual age</LI>
<LI>Oxygen requirement at, or death before, 28 days of age</LI>
<LI>Culture-proven sepsis Grade 3 or 4 intracranial haemorrhage</LI>
<LI>Periventricular leukomalacia</LI>
<LI>Vitamin A on study day 28 in subset of infants and relative dose-response to 2000 IU vitamin A intramuscular</LI>
<LI>Examination for potential toxicity weekly</LI>
<LI>Assessment of neurodevelopmental status at 18 to 22 months corrected age is available in Ambalavanan 2005 (companion paper for <LINK REF="STD-Tyson-1999" TYPE="STUDY">Tyson 1999</LINK>)</LI>
<LI>Additional subgroup analysis of 'small for gestational age' infants</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-02 17:57:13 -0400" MODIFIED_BY="[Empty name]">
<P>A subgroup analysis of 'small for gestational age' (SGA) infants from the original NICHD trial was performed to test the hypothesis that in infants requiring early respiratory support, vitamin A supplementation decreases the relative risk of BPD or death in premature SGA infants to a greater extent than in gestational age-equivalent vitamin A-treated 'appropriate for gestational age' (AGA) infants. Although vitamin A supplementation significantly increased serum retinol concentrations in AGA ELBW infants (median [5th percentile, 95th percentile]: 16.3 [&#8722;7.0, 68.8] versus 2.4 [&#8722;13.9, 55.1]; P &lt; 0.001), no increases were noted in SGA ELBW infants. Given the limited power of this analysis due to a low number of SGA infants, these data did not provide evidence to support the hypothesis that vitamin A supplementation in preterm SGA infants requiring early respiratory support decreases the relative risk of BPD or death as compared with preterm AGA infants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-18 18:18:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wardle-2001">
<CHAR_METHODS MODIFIED="2016-07-18 18:18:59 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-31 11:15:44 -0400" MODIFIED_BY="[Empty name]">
<P>Number: 154</P>
<P>Description: birth weight &lt; 1000 grams; no life-threatening congenital abnormalities; consent before 24 hours of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-14 06:40:48 -0500" MODIFIED_BY="[Empty name]">
<P>Vitamin A (form not stated) versus control</P>
<OL>
<LI>Supplemental 5000 IU vitamin A orally daily until day 28 (n = 77)</LI>
<LI>Same volume look-alike placebo liquid (n = 77)</LI>
</OL>
<P>Other: control and study infants received 23 IU/kg/d vitamin A (stated amount but probably 233 IU) in intralipid when on parenteral nutrition; when on full enteral feeds and more than 14 days of age all infants received 5000 IU/kg/d vitamin A orally; antenatal steroids received by 77% in the vitamin A group and 82% in the control group; all but 1 infant in the control group received an artificial surfactant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-02 04:15:33 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Oxygen requirement at 28 days</LI>
<LI>Death pre-discharge</LI>
<LI>Oxygen requirement at 36 weeks' postmenstrual age</LI>
<LI>Retinopathy of prematurity requiring treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-29 14:40:07 -0400" MODIFIED_BY="[Empty name]">
<P>Location: Liverpool Women&#8217;s Hospital, Liverpool, UK</P>
<P>Trial author provided further information on the numbers examined for retinopathy of prematurity and numbers with any retinopathy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-02 18:01:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Werkman-1994">
<CHAR_METHODS MODIFIED="2016-07-18 18:20:32 -0400" MODIFIED_BY="[Empty name]">
<P>Single centre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-31 11:16:40 -0400" MODIFIED_BY="[Empty name]">
<P>Number: 86</P>
<P>Description: birth weight 725 to 1300 grams; &lt; 96 hours of age; no intraventricular or periventricular haemorrhage, history of maternal substance abuse, or sexually transmitted disease; no congenital anomalies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 18:01:13 -0400" MODIFIED_BY="[Empty name]">
<P>Vitamin A (retinyl palmitate) versus control</P>
<OL>
<LI>Supplemental vitamin A 80,000 RE/L (giving about 1300 to 3300 IU/kg/d) in intravenous lipid infused over 16 h from randomisation (48 to 96 h) and while receiving parenteral nutrition (n = 44)</LI>
<LI>No supplementation (n = 42)</LI>
</OL>
<P>Other: both control and study infants received vitamin A as multivitamin preparation added to protein-dextrose solution (birth weight &lt; 1000 grams 1.5 mL/d, 210 RE/d; &gt; 1000 grams 3.4 mL/d, 476 RE/d) and oral supplements when fed orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-14 06:45:50 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Bronchopulmonary dysplasia (oxygen beyond 28 days and characteristic chest x-ray)</LI>
<LI>Total days oxygen requirement</LI>
<LI>Vitamin A and retinol-binding protein levels at various times</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-19 04:00:57 -0400" MODIFIED_BY="Karla Soares-Weiser">
<P>Location: Newborn Centre, University of Tennessee, Tennessee, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>h: hour<BR/>IU: international units<BR/>wk: week</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-19 11:42:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aranda-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-19 11:42:37 -0400" MODIFIED_BY="[Empty name]">
<P>Route of supplementation not stated and reported vitamin A levels appear to contain a decimal point error; no clinical outcomes. Published as abstract only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-19 11:44:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aurvag-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-19 11:44:48 -0400" MODIFIED_BY="[Empty name]">
<P>Compared vitamin A supplementation of human milk fortifier given to VLBW infants to historical controls; no clinical outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 18:13:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coutsoudis-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 18:13:05 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind placebo-controlled trial was designed to determine whether high-dose (25,000 IU) enteral vitamin A, to correct deficiency, would be absorbed and well tolerated in low birth weight (LBW) neonates.</P>
<P>Thirty-five LBW infants (950 to 1700 grams; gestational age 27 to 36 weeks) were allocated to receive either placebo or vitamin A (25,000 IU) via nasogastric tube on the first day of the study (between 36 and 60 hours after delivery). The dose was repeated on study days 4 and 8.</P>
<P>Serum retinol concentrations were determined pre- and post-supplementation. Toxic effects of vitamin A were monitored by noting vomiting, drowsiness and irritability, and palpating for a bulging fontanelle. Included a broad population of preterm or low birth weight infants and did not report on relevant clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 18:15:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coutsoudis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 18:15:06 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial to investigate the effect of vitamin A supplementation on the incidence and severity of respiratory infections in LBW infants during their first year of life.</P>
<P>The primary outcome was incidence of respiratory infections during the first year of life.</P>
<P>One hundred and thirty LBW infants (gestational age &lt; 36 weeks and birth weight 950 to 1700 grams) were enrolled in the study. The infants were randomly allocated to a vitamin A or placebo group. Infants in the vitamin A group received 25,000 IU of vitamin A (retinyl palmitate, Arovit drops, Roche, Basle, Switzerland) on study days 1, 4 and 8. Study day 1 was between 36 and 60 hours after delivery. Infants in the placebo group received a placebo (formulated by Roche) with a similar appearance and packed in the same dropper bottles as the vitamin A drops.</P>
<P>Included a broad population of preterm or low birth weight infants and did not report on relevant clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-19 12:07:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koo-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-19 12:07:45 -0400" MODIFIED_BY="[Empty name]">
<P>Formula-fed infants with birth weights &#8804; 1500 grams (n = 61) were randomly assigned to receive one of three preterm infant formulas. Experimental formula feedings were continued until infants weighed approximately 2 kg or until hospital discharge. Investigators measured vitamin A status as indicated by serum retinol and retinol-binding protein (RBP) concentrations. Relevant clinical outcomes not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 18:16:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Landman-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 18:16:15 -0400" MODIFIED_BY="[Empty name]">
<P>Compared 2000 IU of intramuscular vitamin A administered on alternate days for 28 days to giving 5000 IU of vitamin A per day with the early introduction of feeds.</P>
<P>The vitamin A status of 10 preterm infants (mean gestation 30.5 weeks) who received intramuscular vitamin supplementation was compared with that of nine infants (mean gestation 30.7 weeks) given enteral vitamin A. Vitamin A status was evaluated on the 32nd day of life using plasma retinol and retinol-binding protein (RBP) concentrations and a modified relative dose response (RDR) test. Relevant clinical outcomes not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 18:16:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Longardt-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 18:16:50 -0400" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial. Prospective study of 69 preterm infants (median birth weight 995&#8201;grams, gestational age 28 weeks), in which 51 received 5000 &#8201;IU vitamin A three times per week intramuscular (IM) for 4 weeks and 18 infants without IM vitamin A served as controls. Serum retinol, retinyl palmitate, total retinol-binding protein 4 (RBP4), retinol-unbound RBP4 (apo-RBP4) and transthyretin concentrations were determined at days 3 (D3) and 28 (D28) of life.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 18:18:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robbins-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 18:18:19 -0400" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
<P>Evaluated two regimens of vitamin A supplementation on the incidence of BPD. In group I (n = 24), vitamin A levels were measured after 1 week of parenteral nutrition and, if low, the infant was given a supplement of 2000 IU intramuscularly three times a week, beginning on the 10th to 14th day of life. In group II (n = 24), the same supplementation was begun on the second to fourth day of life. In both groups, when enteral feedings reached 60 kcal/kg per day, 2500 IU/d vitamin A was given orally.</P>
<P>Reported on the incidence of oxygen support at 28 days, BPD at 36 weeks' gestational age and length of neonatal intensive care unit stay.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-19 12:17:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rush-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-19 12:17:45 -0400" MODIFIED_BY="[Empty name]">
<P>Compared enteral with intramuscular administration of vitamin A; vitamin A concentrations only reported graphically; no relevant clinical outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmiedchen-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-08-02 19:19:35 -0400" MODIFIED_BY="[Empty name]">
<P>Studied the impact of urinary retinol excretion on the serum retinol concentration of 63 VLBW infants treated with vitamin A (5000 IU intramuscular, 3 times/week for 4 weeks) compared to 38 untreated infants classified as control group. Groups not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-08-02 18:20:47 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-08-02 18:20:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calisici--2014">
<CHAR_METHODS MODIFIED="2016-07-19 11:16:10 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-08-02 18:19:43 -0400" MODIFIED_BY="[Empty name]">
<P>Infants gestational age &lt; 32 weeks and birth weight &lt; 1250 grams, having an oxygen support of FiO&#8322; &gt; 0.21 within the first 24 hours of life.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-02 18:19:53 -0400" MODIFIED_BY="[Empty name]">
<P>Intervention: Oral Vitamin A was administered at a dose of 30,000 IU/kg for 6 weeks beginning in the first two days of life.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-02 18:20:35 -0400" MODIFIED_BY="[Empty name]">
<P>BPD and mortality rates were compared between control and therapy groups.</P>
<P>The study enrolled 209 infants. There were 110 patients in Group 1 and 99 patients in Group 2. Prematurity-related problems and diseases during postnatal period; RDS, late-onset sepsis, PDA, pneumothorax, severe intracranial haemorrhage, ROP, BPD, and mortality were similar between the groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-02 18:20:47 -0400" MODIFIED_BY="[Empty name]">
<P>Presented at EAPS 2014 and published as an abstract; awaiting publication in peer-reviewed literature</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-08-02 18:27:38 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-08-02 18:27:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2013">
<CHAR_STUDY_NAME MODIFIED="2014-06-03 17:54:25 -0400" MODIFIED_BY="[Empty name]">
<P>NeoVitaA Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-18 18:19:21 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre, double-blind randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-14 06:46:36 -0500" MODIFIED_BY="[Empty name]">
<P>ELBW neonates requiring mechanical ventilation, noninvasive ventilatory support or supplemental oxygen at 24 hours of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-14 06:47:43 -0500" MODIFIED_BY="[Empty name]">
<P>Postnatal high-dose oral vitamin A supplementation (5000 IU vitamin A/kg/day versus placebo) for 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-02 18:23:15 -0400" MODIFIED_BY="[Empty name]">
<P>The primary endpoint is the proportion of children who died before 36 weeks' gestational age or developed moderate or severe BPD. BPD is defined as the need for supplemental oxygen to maintain SaO&#8322; of &#8805; 92% at rest at 36 weeks' postmenstrual age (PMA).</P>
<P>Clinical secondary endpoints include the following: BPD (including mild form), intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotising enterocolitis, total number of days of mechanical ventilation and oxygen supplementation, and safety and tolerability of high-dose vitamin A supplementation.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-06-03 17:53:09 -0400" MODIFIED_BY="[Empty name]"/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2016-08-02 18:27:38 -0400" MODIFIED_BY="[Empty name]">
<P>Meyer S, Gortner L, NeoVitaA Trial Investigators. Early Postnatal Additional High-Dose Oral Vitamin A Supplementation versus Placebo for 28 Days for Preventing Bronchopulmonary Dysplasia or Death in Extremely Low Birth Weight Infants. Neonatology 2014;105(3):182-8. [PubMed: 24434948]</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BPD: bronchopulmonary dysplasia<BR/>ELBW: extremely low birth weight<BR/>IU: international units<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-08-02 17:50:44 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-08-02 17:36:02 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-02 17:36:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>"random assignment stratified by birth weight (401-750 grams, 751-1000 grams)" (pg 657)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 06:54:28 -0400" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>Random numbers were computer-generated in blocks of 10 (pg 142)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-26 08:59:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION>
<P>Randomised controlled trial to assess the effect of vitamin A supplementation for prevention of bronchopulmonary dysplasia in VLBW premature infants. Infants were assigned to vitamin A or control group "by a research nurse using a randomization list (with sealed envelopes containing the treatment assignments randomised by blocks of 4)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-14 06:33:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION>
<P>Randomisation was undertaken by the pharmacy staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 06:55:23 -0400" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>Randomised, blind controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-18 18:17:57 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>Multicentre randomised controlled trial; infants were stratified according to hospital, gender, and weight (pg 421)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-18 18:18:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>Block randomisation was performed with stratification by weight; the categories were 500 to 750 grams, 750 to 1000 grams, 1000 to 1250 grams, and 1250 to 1500 grams (pg 645)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-18 18:18:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>Single centre randomised controlled trial; sealed envelopes containing cards indicating group designation were used for randomisation (pg 270)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-18 18:18:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>"The infants were stratified according to center and birth weight (401 to 750 grams or 751 to 1000 grams) and assigned to the vitamin A or control group by a hospital pharmacist using a randomization list." (pg 1962)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 08:38:22 -0400" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Randomisation assigned using a computerised random number generator (pg F10)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:57 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>Eligible infants were randomly assigned; method of sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-18 18:17:59 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:50 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>Used "shuffled blocks (of sizes 3, 6, or 9) of sealed opaque envelopes" (pg 657)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-07 12:21:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION>
<P>"..control infants received a sham procedure rather than a placebo injection. For each treatment, a screen was placed around the bed, a pacifier was used for non-pharmacological pain management, and the injection site was covered with cotton and tape. The same covering was placed on the control infants".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-14 06:33:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION>
<P>Randomisation was undertaken by the pharmacy staff and vitamin A or and empty box were delivered in a sealed bag to the infants bedside</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:52 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-18 18:17:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>Randomisation was performed using sequential sealed envelopes; randomisation and drug preparation performed by someone not involved with patients (pg 421)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:53 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>"Sealed envelopes containing cards with the group designation were maintained in the pharmacy department" (pg 645)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 10:05:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>Randomisation was carried out by pharmacists who had no knowledge of the clinical status of the infants (pg 270)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:55 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>Sealed envelopes containing the treatment assignments were used (pg 1963)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:56 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Sealed opaque numbered envelopes containing the treatment allocation (pg F10)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:58 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>Method of allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-08-02 17:50:44 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-22 04:30:37 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>Blinding of intervention: interventions were not provided in the same way for the three groups</P>
<P>Blinding of outcome measurements: yes ("Outcome evaluations were performed by one of the investigators, masked to treatment group assignment", pg 657)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>Blinding of intervention: unclear because no information about the control group intervention</P>
<P>Blinding of outcome measurement: 2 investigators administered the vitamin A and were not involved in the treatment of study infants; and the intensive care unit staff were unaware of the group allocation of infants (pg 142)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-12-03 19:12:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION>
<P>Attending neonatologist unaware of intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-01 16:04:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-19 04:00:52 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="NO" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>Blinding of intervention: no information provided</P>
<P>Blinding of outcome measurement: no<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-19 04:00:53 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>Blinding of intervention: "Opaque tape concealed the contents of syringes to ensure blinding" (pg 421)</P>
<P>Blinding of outcome: "At all sites, staff responsible for patient care had no knowledge of group designation" (pg 421)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-08-02 17:50:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>Blinding of intervention: none &#8211; infants in the intervention group received intramuscular injections and the placebo group did not receive these</P>
<P>Blinding of outcome measurement: yes &#8211; "The staff responsible for the care of these infants had no knowledge of group assignment or outcome of study echocardiograms" (pg 645)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-19 04:00:54 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>Blinding of intervention: control group received intramuscular saline solution exactly in the same manner of the intervention (pg 270&#8211;1)</P>
<P>Blinding of outcome measurement: neonatal intensive care unit staff responsible for patient management had no knowledge of the group designation (pg 270)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-14 06:40:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>Blinding of intervention: yes</P>
<P>Blinding of outcome: outcome were assessed by research nurses that transmitted the data electronically to a biostatistical co-ordinating centre (pg 1963)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-12-02 17:43:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Blinding of intervention: "The control group received an equivalent volume of an inert placebo solution (which had been prepared in the hospital pharmacy to look identical with the vitamin A solution) given in the same way" (pg F10)</P>
<P>Blinding of outcome: "Both the medical and nursing staff caring for the infants and administering the vitamin A and placebo solutions were unaware of the treatment allocation" (pg F10)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-19 04:00:58 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="NO" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>Blinding of intervention: details not reported</P>
<P>Blinding of outcome: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-12-02 17:18:49 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-12-02 17:18:49 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-08-02 17:45:17 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:16:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants; intention-to-treat analysis was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:17:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-08-02 17:43:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION>
<P>Complete follow-up of enrolled infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-08-02 17:45:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION>
<P>Clinical outcomes reported on all enrolled infants; some loss to follow-up on retinol levels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-19 04:00:52 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>No information provided in the conference proceeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:18:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:18:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:18:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants; all but one infant enrolled in the study completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:18:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants; intention-to-treat analysis was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:19:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Detailed outcome information is provided for all randomised participants; intention-to-treat analysis was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-18 18:20:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>12/98 randomised participants left the study early (10 transferred to another hospital, 2 died from sepsis) and their data were not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-08-02 17:43:46 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:50 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>Authors reported all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-02 17:43:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION>
<P>Incomplete reporting of death at 36 weeks' postmenstrual age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-01 16:05:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:52 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>Based on the conference proceeding, no relevant information is provided to make a judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:53 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>All clinically relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:54 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>Authors reported all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:55 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>All clinically relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:56 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>Authors reported all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:57 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Authors reported all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:58 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="NO" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>Not all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-08-02 17:46:48 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:50 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Ambalavanan-2003">
<DESCRIPTION>
<P>Source of funding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:51 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Bental-1994">
<DESCRIPTION>
<P>Poor reporting of study design; supported by a grant from the South African Medical Research Council</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kiatchoosakun-2014">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-01 16:05:47 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mactier-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-02 17:46:48 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Papagaroufalis-1988">
<DESCRIPTION>
<P>Report of the study is poor and only based on an abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:53 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="NO" STUDY_ID="STD-Pearson-1992">
<DESCRIPTION>
<P>Small study; sample size calculation performed based on high incidence rate of bronchopulmonary dysplasia; blinded interim analysis performed of the 49 patients enrolled (pg 423)</P>
<P>161 infants eligible, 74 of them met the inclusion criteria and 49 were enrolled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:54 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Ravishankar-2003">
<DESCRIPTION>
<P>Small sample size; source of funding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:55 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Shenai-1987">
<DESCRIPTION>
<P>Sample size calculation performed based on high incidence rate of bronchopulmonary dysplasia</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:56 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="YES" STUDY_ID="STD-Tyson-1999">
<DESCRIPTION>
<P>Study protocol described in detail, including sample size calculation</P>
<P>Supported by cooperative agreements with the National Institute of Child Health and Human Development, and by General Clinical Research Center grants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:57 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Wardle-2001">
<DESCRIPTION>
<P>Study protocol described in detail, including sample size calculation; source of funding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-19 04:00:58 -0400" MODIFIED_BY="Karla Soares-Weiser" RESULT="UNKNOWN" STUDY_ID="STD-Werkman-1994">
<DESCRIPTION>
<P>Supported by a grant of the National Eye Institute and a gift from Ross Laboratories (pg 586)</P>
<P>Not enough detail of protocol is provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-07-19 15:29:05 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-07-19 15:29:05 -0400" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-02-25 19:15:16 -0500" MODIFIED_BY="GDT">Supplemental vitamin A compared to no supplementation in very low birth weight infants</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Supplemental vitamin A compared to no supplementation in very low birth weight infants</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>very low birth weight infants<BR/>
<B>Intervention: </B>supplemental vitamin A<BR/>
<B>Comparison: </B>no supplementation</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>no supplementation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Supplemental vitamin A</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Neonatal death</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>144 per 1000<BR/>(111 to 186)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.86<BR/>(0.66 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1165<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: 95% CI are wide and imprecise</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chronic lung disease (oxygen use at 28 days in survivors)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>725 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>674 per 1000<BR/>(623 to 732)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.93<BR/>(0.86 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1070<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>MODERATE <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: although the 95% CI is narrow, the result is consistent with minimal clnical effect </I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Death or chronic lung disease (oxygen use at 28 days)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>798 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>742 per 1000<BR/>(702 to 790)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.93<BR/>(0.88 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1165<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>MODERATE<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: although the 95% CI is narrow, the result is consistent with minimal clnical effect </I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Death before 36 weeks' postmenstrual age</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>168 per 1000<BR/>(129 to 216)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.00<BR/>(0.77 to 1.29)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1089<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: 95% CI are wide and imprecise</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chronic lung disease (oxygen use at 36 weeks' postmenstrual age in survivors)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>546 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>486 per 1000<BR/>(426 to 546)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.87<BR/>(0.77 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>986<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: although the 95% CI is narrow, the result is consistent with minimal clnical effect </I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Death or chronic lung disease (oxygen use at 36 weeks' postmenstrual age)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>622 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>573 per 1000<BR/>(523 to 629)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.92<BR/>(0.84 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1089<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Imprecision: although the 95% CI is narrow, the result is consistent with minimal clnical effect </I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Neurodevelopmental impairment at 18 to 22 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>481 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>428 per 1000<BR/>(356 to 520)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 0.89<BR/>(0.74 to 1.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>538<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Concerning imprecision: does not met the optimal information size criteria</I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>
<I>1 </I>
</SUP>
<I>Imprecision: 95% CI are wide and imprecise</I>
</P>
<P>
<SUP>
<I>2 </I>
</SUP>
<I>Imprecision: although the 95% CI is narrow, the result is consistent with minimal clnical effect </I>
</P>
<P>
<SUP>
<I>3</I>
</SUP>
<I> Concerning imprecision; does not met the optimal information size criteria</I>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-07-21 05:42:27 -0400" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-08-02 19:13:07 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-08-02 19:13:07 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Supplemental vitamin A versus no supplementation</NAME>
<DICH_OUTCOME CHI2="4.691006829242507" CI_END="1.1104018104264828" CI_START="0.66174398024151" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8572057592544507" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.045480161195785455" LOG_CI_START="-0.1793100007025275" LOG_EFFECT_SIZE="-0.06691491975337104" METHOD="MH" MODIFIED="2016-08-02 18:44:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45474095935511005" P_Q="0.9766100146344957" P_Z="0.2432615108103684" Q="8.596155339431345E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="578" WEIGHT="100.0" Z="1.1668734221947226">
<NAME>Death (before 1 month)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.693047922444267" CI_END="1.177298308697718" CI_START="0.6211808693302201" DF="4" EFFECT_SIZE="0.8551696830792391" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="68" I2="14.767544118392648" ID="CMP-001.01.01" LOG_CI_END="0.07088652011318455" LOG_CI_START="-0.2067819278183283" LOG_EFFECT_SIZE="-0.06794770385257189" MODIFIED="2014-10-01 16:18:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32026671198134216" P_Z="0.33743891284259053" STUDIES="5" TAU2="0.0" TOTAL_1="510" TOTAL_2="501" WEIGHT="70.48858060953377" Z="0.9592379211633154">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.2053422336414767" CI_START="0.18151070468113498" EFFECT_SIZE="0.46774193548387094" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.08111037394796876" LOG_CI_START="-0.7410977571465645" LOG_EFFECT_SIZE="-0.3299936915992978" ORDER="1" O_E="0.0" SE="0.4829691262008177" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="0.23325917686318137" WEIGHT="10.515563231085666"/>
<DICH_DATA CI_END="2.5762242033955722" CI_START="0.5283356585646193" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4109836560714824" LOG_CI_START="-0.27709007681025594" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="2" O_E="0.0" SE="0.40417791671464237" STUDY_ID="STD-Papagaroufalis-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.16335978835978837" WEIGHT="7.993061552778312"/>
<DICH_DATA CI_END="1.693297579929136" CI_START="0.024505556137594475" EFFECT_SIZE="0.2037037037037037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2287332876803513" LOG_CI_START="-1.6107354370098381" LOG_EFFECT_SIZE="-0.6910010746647435" ORDER="3" O_E="0.0" SE="1.0805130344000564" STUDY_ID="STD-Pearson-1992" TOTAL_1="27" TOTAL_2="22" VAR="1.1675084175084176" WEIGHT="4.485901891865379"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="4" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Shenai-1987" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.5088175756976935"/>
<DICH_DATA CI_END="1.3734198863514975" CI_START="0.6268447257716409" EFFECT_SIZE="0.9278582930756843" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" LOG_CI_END="0.137803331444814" LOG_CI_START="-0.2028400239091861" LOG_EFFECT_SIZE="-0.03251834623218605" ORDER="5" O_E="0.0" SE="0.20009559314674352" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.040038246396747114" WEIGHT="46.98523635810671"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3274451372085478" CI_START="0.5598445317828697" DF="0" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.12301658090231653" LOG_CI_START="-0.25193255935615344" LOG_EFFECT_SIZE="-0.0644579892269185" MODIFIED="2010-07-21 10:21:21 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5003877006541921" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="29.511419390466223" Z="0.6738798617516083">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.3274451372085476" CI_START="0.5598445317828697" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.12301658090231646" LOG_CI_START="-0.25193255935615344" LOG_EFFECT_SIZE="-0.0644579892269185" ORDER="6" O_E="0.0" SE="0.22024698101600318" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.048508732646663666" WEIGHT="29.511419390466223"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.642908676796013" CI_END="1.0055713694000907" CI_START="0.8634758282547842" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9318189583079113" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="379" I2="21.495856437273794" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0024128996335851696" LOG_CI_START="-0.06374981536635113" LOG_EFFECT_SIZE="-0.03066845786638298" METHOD="MH" MODIFIED="2016-08-02 18:46:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2654491516814488" P_Q="0.9802682150221151" P_Z="0.06921597332678348" Q="0.03985812512851898" RANDOM="NO" SCALE="3.58" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="523" WEIGHT="100.00000000000001" Z="1.8170074453429745">
<NAME>Chronic lung disease (oxygen use at 28 days in survivors)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.644285749447954" CI_END="1.009240885923312" CI_START="0.8550916119963394" DF="4" EFFECT_SIZE="0.9289743893330852" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="322" I2="47.673332328152874" ID="CMP-001.02.01" LOG_CI_END="0.003994836149148435" LOG_CI_START="-0.06798735374773203" LOG_EFFECT_SIZE="-0.0319962587992918" MODIFIED="2014-10-01 15:22:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10551277529881686" P_Z="0.08143541007330778" STUDIES="5" TAU2="0.0" TOTAL_1="451" TOTAL_2="433" WEIGHT="84.66399384631123" Z="1.742417533461355">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.4931337467360493" CI_START="0.4327600527854668" EFFECT_SIZE="0.8038461538461539" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.1740987111864267" LOG_CI_START="-0.36375283490595456" LOG_EFFECT_SIZE="-0.09482706185976394" ORDER="7" O_E="0.0" SE="0.3159366605827567" STUDY_ID="STD-Bental-1994" TOTAL_1="26" TOTAL_2="19" VAR="0.09981597350018404" WEIGHT="3.002194850644378"/>
<DICH_DATA CI_END="1.0594333993454672" CI_START="0.5179153737574573" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.025073660238988844" LOG_CI_START="-0.28574119722900115" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="8" O_E="0.0" SE="0.18257418583505539" STUDY_ID="STD-Papagaroufalis-1988" TOTAL_1="18" TOTAL_2="20" VAR="0.03333333333333334" WEIGHT="4.430364465829457"/>
<DICH_DATA CI_END="2.0145937639260034" CI_START="0.5352951975599958" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.30418748528012807" LOG_CI_START="-0.2714066529037893" LOG_EFFECT_SIZE="0.016390416188169384" ORDER="9" O_E="0.0" SE="0.338106846006169" STUDY_ID="STD-Pearson-1992" TOTAL_1="26" TOTAL_2="18" VAR="0.1143162393162393" WEIGHT="2.4563412414363093"/>
<DICH_DATA CI_END="0.8658856475167014" CI_START="0.2833833823742947" EFFECT_SIZE="0.4953560371517028" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-0.06253945894301487" LOG_CI_START="-0.5476256204073413" LOG_EFFECT_SIZE="-0.3050825396751781" ORDER="10" O_E="0.0" SE="0.28494201245937095" STUDY_ID="STD-Shenai-1987" TOTAL_1="19" TOTAL_2="20" VAR="0.0811919504643963" WEIGHT="4.30344202703314"/>
<DICH_DATA CI_END="1.05567267739229" CI_START="0.8890798372471407" EFFECT_SIZE="0.9688019881287354" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="269" LOG_CI_END="0.023529281419100365" LOG_CI_START="-0.0510592386708817" LOG_EFFECT_SIZE="-0.013764978625890673" ORDER="11" O_E="0.0" SE="0.043813665919984625" STUDY_ID="STD-Tyson-1999" TOTAL_1="362" TOTAL_2="356" VAR="0.001919637321348022" WEIGHT="70.47165126136795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.700478891849806" CI_START="0.5358237783253037" DF="0" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.230571245377798" LOG_CI_START="-0.2709780175543719" LOG_EFFECT_SIZE="-0.02020338608828695" NO="2" P_CHI2="1.0" P_Z="0.8745337291301328" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="42" WEIGHT="3.9877096182530423" Z="0.1579023718120996">
<NAME>Supplementation via intravenous route</NAME>
<DICH_DATA CI_END="1.7004788918498055" CI_START="0.5358237783253038" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.23057124537779788" LOG_CI_START="-0.27097801755437184" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="12" O_E="0.0" SE="0.29461251975524866" STUDY_ID="STD-Werkman-1994" TOTAL_1="44" TOTAL_2="42" VAR="0.08679653679653679" WEIGHT="3.9877096182530423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9874841299953613E-30" CI_END="1.1134737230798557" CI_START="0.8021103961954497" DF="0" EFFECT_SIZE="0.9450549450549451" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" I2="100.0" ID="CMP-001.02.03" LOG_CI_END="0.04667997255454351" LOG_CI_START="-0.09576585470959514" LOG_EFFECT_SIZE="-0.02454294107752584" NO="3" P_CHI2="0.0" P_Z="0.49942769209915816" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="11.348296535435747" Z="0.6753905187751263">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.1134737230798555" CI_START="0.8021103961954495" EFFECT_SIZE="0.945054945054945" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.046679972554543425" LOG_CI_START="-0.09576585470959521" LOG_EFFECT_SIZE="-0.02454294107752589" ORDER="13" O_E="0.0" SE="0.08367338405317198" STUDY_ID="STD-Wardle-2001" TOTAL_1="52" TOTAL_2="48" VAR="0.007001235198909616" WEIGHT="11.348296535435747"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.881532973532433" CI_END="0.9922860018497046" CI_START="0.8766398166435125" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9326721925303924" ESTIMABLE="YES" EVENTS_1="435" EVENTS_2="461" I2="36.56056484454388" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.0033631351811700028" LOG_CI_START="-0.05717880774564836" LOG_EFFECT_SIZE="-0.030270971463409166" METHOD="MH" MODIFIED="2016-08-02 18:49:30 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16288665754174192" P_Q="0.6247336201339524" P_Z="0.027458698166172073" Q="0.23927036414719" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="578" WEIGHT="99.99999999999999" Z="2.204934399890159">
<NAME>Death or chronic lung disease (oxygen use at 28 days)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.704295086387176" CI_END="0.9962397594888854" CI_START="0.8646906544605507" DF="4" EFFECT_SIZE="0.9281374950038739" ESTIMABLE="YES" EVENTS_1="367" EVENTS_2="390" I2="48.08090869899759" ID="CMP-001.03.01" LOG_CI_END="-0.0016361297567613349" LOG_CI_START="-0.06313923483511685" LOG_EFFECT_SIZE="-0.03238768229593909" NO="1" P_CHI2="0.10303106445465637" P_Z="0.03899463994259058" STUDIES="5" TAU2="0.0" TOTAL_1="510" TOTAL_2="501" WEIGHT="84.68472424948635" Z="2.064243447933033">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.138177964162619" CI_START="0.49208758581982465" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.056210173140853845" LOG_CI_START="-0.3079575910275999" LOG_EFFECT_SIZE="-0.125873708943373" ORDER="14" O_E="0.0" SE="0.21391394733205527" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="0.04575917686318132" WEIGHT="4.457967589351389"/>
<DICH_DATA CI_END="1.0503003242444813" CI_START="0.6679853354424152" EFFECT_SIZE="0.8376068376068376" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" LOG_CI_END="0.021313499558357117" LOG_CI_START="-0.17523307166569063" LOG_EFFECT_SIZE="-0.07695978605366678" ORDER="15" O_E="0.0" SE="0.11545242885822425" STUDY_ID="STD-Papagaroufalis-1988" TOTAL_1="27" TOTAL_2="28" VAR="0.013329263329263333" WEIGHT="5.506439732066877"/>
<DICH_DATA CI_END="1.5247197577390372" CI_START="0.5110366150126265" EFFECT_SIZE="0.8827160493827161" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.1831900280423243" LOG_CI_START="-0.2915479821974626" LOG_EFFECT_SIZE="-0.05417897707756912" ORDER="16" O_E="0.0" SE="0.27886345720590167" STUDY_ID="STD-Pearson-1992" TOTAL_1="27" TOTAL_2="22" VAR="0.07776482776482775" WEIGHT="2.8526296885118825"/>
<DICH_DATA CI_END="0.8889865388127346" CI_START="0.3152767835869751" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="-0.05110481514183409" LOG_CI_START="-0.501308008736064" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="17" O_E="0.0" SE="0.2644515844590004" STUDY_ID="STD-Shenai-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.06993464052287582" WEIGHT="3.6670378557567873"/>
<DICH_DATA CI_END="1.0461342101094795" CI_START="0.9003989518579203" EFFECT_SIZE="0.9705349794238683" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="315" LOG_CI_END="0.019587404388768284" LOG_CI_START="-0.04556501922747766" LOG_EFFECT_SIZE="-0.01298880741935472" ORDER="18" O_E="0.0" SE="0.038270856141881124" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.00146465842983256" WEIGHT="68.20064938379942"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.062730969796553" CI_START="0.8631331389257341" DF="0" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="71" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.02642333684655286" LOG_CI_START="-0.06392220887223088" LOG_EFFECT_SIZE="-0.01874943601283899" MODIFIED="2010-07-21 10:21:38 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4159293148948807" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="15.31527575051364" Z="0.8135037322147112">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.062730969796553" CI_START="0.8631331389257342" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="71" LOG_CI_END="0.02642333684655286" LOG_CI_START="-0.06392220887223082" LOG_EFFECT_SIZE="-0.01874943601283899" ORDER="19" O_E="0.0" SE="0.05306942077287748" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.0028163634211687202" WEIGHT="15.31527575051364"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5986193279976412" CI_END="1.2943998465916997" CI_START="0.7716964429503571" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9994417228484623" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.11206845279694999" LOG_CI_START="-0.11255350157794843" LOG_EFFECT_SIZE="-2.4252439049921948E-4" METHOD="MH" MODIFIED="2014-10-01 15:25:10 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.896748380265552" P_Q="0.44416702390016005" P_Z="0.9966230854458145" Q="0.5854939673610469" RANDOM="NO" SCALE="3.26" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="546" TOTAL_2="543" WEIGHT="100.0" Z="0.004232347386290194">
<NAME>Death before 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.005808683352832754" CI_END="1.463772453876877" CI_START="0.7722693734868873" DF="2" EFFECT_SIZE="1.06321523497496" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="62" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.16547357009239647" LOG_CI_START="-0.11223118798874758" LOG_EFFECT_SIZE="0.026621191051824415" MODIFIED="2014-10-01 15:24:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9970998718466737" P_Z="0.7070878011640578" STUDIES="3" TAU2="0.0" TOTAL_1="469" TOTAL_2="466" WEIGHT="68.29495655155418" Z="0.37577012398102355">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="5.132740824421274" CI_START="0.23370486184562464" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7103493352980831" LOG_CI_START="-0.6313322527307358" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2014-10-01 15:24:33 -0400" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.7881104062391006" STUDY_ID="STD-Mactier-2012" TOTAL_1="42" TOTAL_2="46" VAR="0.6211180124223602" WEIGHT="3.1307488044703553"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" ORDER="20" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Ravishankar-2003" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="4.810420385281435"/>
<DICH_DATA CI_END="1.496650476088788" CI_START="0.7575308359533008" EFFECT_SIZE="1.0647811447811448" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="55" LOG_CI_END="0.17512038816562228" LOG_CI_START="-0.12059968413021854" LOG_EFFECT_SIZE="0.027260352017701876" ORDER="21" O_E="0.0" SE="0.17370743430454325" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.030174272732667203" WEIGHT="60.35378736180239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3274451372085478" CI_START="0.5598445317828697" DF="0" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.12301658090231653" LOG_CI_START="-0.25193255935615344" LOG_EFFECT_SIZE="-0.0644579892269185" MODIFIED="2010-07-21 10:21:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5003877006541921" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="31.705043448445817" Z="0.6738798617516083">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.3274451372085476" CI_START="0.5598445317828697" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.12301658090231646" LOG_CI_START="-0.25193255935615344" LOG_EFFECT_SIZE="-0.0644579892269185" ORDER="22" O_E="0.0" SE="0.22024698101600318" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.048508732646663666" WEIGHT="31.705043448445817"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.027189822497594" CI_END="0.9868830968853975" CI_START="0.7730535662007478" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8734491957008689" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="261" I2="0.6751562180084106" I2_Q="31.89186397501662" ID="CMP-001.05" LOG_CI_END="-0.005734289462603642" LOG_CI_START="-0.11179041203329386" LOG_EFFECT_SIZE="-0.05876235074794874" METHOD="MH" MODIFIED="2016-08-02 19:13:07 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4023388372574267" P_Q="0.22562179039485186" P_Z="0.02986257365770555" Q="1.4682533664306723" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="494" TOTAL_2="492" WEIGHT="100.00000000000001" Z="2.1719083881484273">
<NAME>Chronic lung disease (oxygen use at 36 weeks' postmenstrual age in survivors)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4146750873814624" CI_END="0.9793747789872008" CI_START="0.7412440974357721" DF="3" EFFECT_SIZE="0.8520303833207631" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="224" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.009051084193358842" LOG_CI_START="-0.1300387519228306" LOG_EFFECT_SIZE="-0.06954491805809472" MODIFIED="2015-12-03 18:38:22 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49090890900804685" P_Z="0.024245678553075543" STUDIES="4" TAU2="0.0" TOTAL_1="442" TOTAL_2="444" WEIGHT="85.31858102126921" Z="2.2532136912736247">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.3122086804282722" CI_START="0.3149387077576484" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.11800290634433365" LOG_CI_START="-0.5017739588221599" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2015-12-03 18:38:22 -0500" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.36405999854376003" STUDY_ID="STD-Kiatchoosakun-2014" TOTAL_1="40" TOTAL_2="40" VAR="0.13253968253968254" WEIGHT="5.341472601409338"/>
<DICH_DATA CI_END="2.4339146033222416" CI_START="0.6798231349838529" EFFECT_SIZE="1.2863247863247864" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.38630533644271464" LOG_CI_START="-0.16760406007531362" LOG_EFFECT_SIZE="0.10935063818370055" MODIFIED="2014-10-01 16:24:38 -0400" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.3253691214104233" STUDY_ID="STD-Mactier-2012" TOTAL_1="39" TOTAL_2="43" VAR="0.10586506516739076" WEIGHT="4.355068253413885"/>
<DICH_DATA CI_END="1.99568364986356" CI_START="0.2174936107414866" EFFECT_SIZE="0.6588235294117647" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3000916992723456" LOG_CI_START="-0.6625534966885303" LOG_EFFECT_SIZE="-0.18123089870809234" ORDER="23" O_E="0.0" SE="0.5654625532779901" STUDY_ID="STD-Ravishankar-2003" TOTAL_1="17" TOTAL_2="14" VAR="0.31974789915966384" WEIGHT="2.0922818945612613"/>
<DICH_DATA CI_END="0.9800859846982802" CI_START="0.7319866559674757" EFFECT_SIZE="0.8470005091497199" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="193" LOG_CI_END="-0.008735821203552872" LOG_CI_START="-0.13549683600788492" LOG_EFFECT_SIZE="-0.07211632860571887" ORDER="24" O_E="0.0" SE="0.07446004757320773" STUDY_ID="STD-Tyson-1999" TOTAL_1="346" TOTAL_2="347" VAR="0.005544298684604359" WEIGHT="73.52975827188472"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2365066645154628" CI_START="0.805370764808512" DF="0" EFFECT_SIZE="0.997920997920998" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.09219646146115759" LOG_CI_START="-0.09400413945764666" LOG_EFFECT_SIZE="-9.038389982445237E-4" MODIFIED="2010-07-21 10:21:56 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.984818945473337" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="14.681418978730807" Z="0.0190277783813868">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.236506664515463" CI_START="0.805370764808512" EFFECT_SIZE="0.997920997920998" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" LOG_CI_END="0.09219646146115767" LOG_CI_START="-0.09400413945764666" LOG_EFFECT_SIZE="-9.038389982445237E-4" ORDER="25" O_E="0.0" SE="0.10937515468754531" STUDY_ID="STD-Wardle-2001" TOTAL_1="52" TOTAL_2="48" VAR="0.011962924462924466" WEIGHT="14.681418978730807"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5890624657960735" CI_END="1.0114446137549538" CI_START="0.8370296450882594" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.920113648457483" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="338" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.0049421059904850816" LOG_CI_START="-0.07725916032185084" LOG_EFFECT_SIZE="-0.036158527165682866" METHOD="MH" MODIFIED="2014-10-13 11:11:49 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.45941030867559984" P_Q="0.3390022040723384" P_Z="0.08465550262276206" Q="0.9142015742552311" RANDOM="NO" SCALE="2.44" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="546" TOTAL_2="543" WEIGHT="100.0" Z="1.7242900056909753">
<NAME>Death or chronic lung disease (oxygen use at 36 weeks' postmenstrual age)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4246415303329645" CI_END="1.0134041173360897" CI_START="0.80724823775819" DF="2" EFFECT_SIZE="0.9044714964311769" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="272" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.005782664443216939" LOG_CI_START="-0.09299289438479175" LOG_EFFECT_SIZE="-0.043605114970787416" MODIFIED="2014-10-01 16:38:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4905045983748104" P_Z="0.08354494779923557" STUDIES="3" TAU2="0.0" TOTAL_1="469" TOTAL_2="466" WEIGHT="80.53901703172328" Z="1.730477780101153">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="2.1604010384167105" CI_START="0.713178151393236" EFFECT_SIZE="1.2412698412698413" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.33453437735685954" LOG_CI_START="-0.1468019701443269" LOG_EFFECT_SIZE="0.09386620360626631" MODIFIED="2014-10-01 16:38:38 -0400" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.28273935317554394" STUDY_ID="STD-Mactier-2012" TOTAL_1="42" TOTAL_2="46" VAR="0.07994154183412495" WEIGHT="4.22190746212615"/>
<DICH_DATA CI_END="1.6188259704401409" CI_START="0.4135228244585782" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.20920016305852931" LOG_CI_START="-0.3835005144963296" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="26" O_E="0.0" SE="0.34815531191139565" STUDY_ID="STD-Ravishankar-2003" TOTAL_1="22" TOTAL_2="18" VAR="0.12121212121212119" WEIGHT="2.919147445241509"/>
<DICH_DATA CI_END="0.9990858564358526" CI_START="0.7902087531670463" EFFECT_SIZE="0.8885304659498208" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="248" LOG_CI_END="-3.971890771681053E-4" LOG_CI_START="-0.10225816393438411" LOG_EFFECT_SIZE="-0.05132767650577613" ORDER="27" O_E="0.0" SE="0.059833640851086195" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.003580064577496771" WEIGHT="73.39796212435562"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.124248786795916" CI_START="0.8627330084763758" DF="0" EFFECT_SIZE="0.9848484848484849" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="66" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.050862427582542696" LOG_CI_START="-0.06412358538056889" LOG_EFFECT_SIZE="-0.006630578899013093" MODIFIED="2010-07-21 10:22:05 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8211706258209622" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="19.460982968276728" Z="0.22603959392671563">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.124248786795916" CI_START="0.8627330084763758" EFFECT_SIZE="0.9848484848484849" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="66" LOG_CI_END="0.050862427582542696" LOG_CI_START="-0.06412358538056889" LOG_EFFECT_SIZE="-0.006630578899013093" ORDER="28" O_E="0.0" SE="0.06754335320447573" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.004562104562104562" WEIGHT="19.460982968276728"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="73" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 09:55:35 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="405" TOTAL_2="402" WEIGHT="0.0" Z="0.0">
<NAME>Death before 18 to 22 months</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="73" EVENTS_2="76" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="405" TOTAL_2="402" WEIGHT="0.0" Z="0.0">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.2742250099517305" CI_START="0.7133693903283486" EFFECT_SIZE="0.953411306042885" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="76" LOG_CI_END="0.105246124978823" LOG_CI_START="-0.1466855295598908" LOG_EFFECT_SIZE="-0.020719702290533916" ORDER="36" O_E="0.0" SE="0.1479859009578431" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.021899826882304543" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="117" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 09:55:35 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="272" TOTAL_2="266" WEIGHT="0.0" Z="0.0">
<NAME>Neurodevelopmental impairment at 18 to 22 months</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="117" EVENTS_2="128" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="272" TOTAL_2="266" WEIGHT="0.0" Z="0.0">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.0757154173589518" CI_START="0.7428136167493536" EFFECT_SIZE="0.8938993566176471" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="128" LOG_CI_END="0.0316973930612682" LOG_CI_START="-0.12912014367094504" LOG_EFFECT_SIZE="-0.048711375304838433" ORDER="35" O_E="0.0" SE="0.09446501713614756" STUDY_ID="STD-Tyson-1999" TOTAL_1="272" TOTAL_2="266" VAR="0.008923639462532652" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="190" EVENTS_2="204" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 09:27:04 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="345" TOTAL_2="342" WEIGHT="0.0" Z="0.0">
<NAME>Death or neurodevelopmental impairment at 18 to 22 months</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="190" EVENTS_2="204" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-21 10:24:19 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="345" TOTAL_2="342" WEIGHT="0.0" Z="0.0">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.0505656919626396" CI_START="0.811404991392128" EFFECT_SIZE="0.9232736572890026" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="204" LOG_CI_END="0.021423214062181034" LOG_CI_START="-0.0907623250425988" LOG_EFFECT_SIZE="-0.03466955549020888" ORDER="37" O_E="0.0" SE="0.06589834099752247" STUDY_ID="STD-Tyson-1999" TOTAL_1="345" TOTAL_2="342" VAR="0.004342591346225751" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-21 10:24:36 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Failure of ductal closure or treatment by day 14</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.722891917246931" CI_START="0.5595051741197536" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.23625803356203937" LOG_CI_START="-0.25219589290459005" LOG_EFFECT_SIZE="-0.00796892967127534" ORDER="34" O_E="0.0" SE="0.28692025429242934" STUDY_ID="STD-Ravishankar-2003" TOTAL_1="22" TOTAL_2="18" VAR="0.08232323232323233" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5542722855175055" CI_END="1.0359771848020471" CI_START="0.7568412344393508" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.885477414391008" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="199" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.01535019110064216" LOG_CI_START="-0.12099521460621845" LOG_EFFECT_SIZE="-0.05282251175278811" METHOD="MH" MODIFIED="2016-07-19 13:54:57 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.7579513200623798" P_Q="1.0" P_Z="0.12885155888236355" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="471" WEIGHT="100.0" Z="1.5186462656614326">
<NAME>Sepsis (&#8805; 1 episodes)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5542722855175055" CI_END="1.0359771848020471" CI_START="0.7568412344393508" DF="2" EFFECT_SIZE="0.885477414391008" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="199" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.01535019110064216" LOG_CI_START="-0.12099521460621845" LOG_EFFECT_SIZE="-0.05282251175278811" MODIFIED="2015-12-03 19:01:07 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7579513200623798" P_Z="0.12885155888236355" STUDIES="3" TAU2="0.0" TOTAL_1="476" TOTAL_2="471" WEIGHT="100.0" Z="1.5186462656614326">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.4134482615341541" CI_START="0.3482693207593224" EFFECT_SIZE="0.7016129032258065" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.1502799160151671" LOG_CI_START="-0.45808478110240014" LOG_EFFECT_SIZE="-0.15390243254361652" ORDER="32" O_E="0.0" SE="0.35735643454067784" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="0.12770362130762575" WEIGHT="6.199009080332884"/>
<DICH_DATA CI_END="1.4348758030171553" CI_START="0.4726546301885152" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.15681431194208062" LOG_CI_START="-0.3254560833421525" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2015-12-03 19:01:07 -0500" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.28328801746691673" STUDY_ID="STD-Kiatchoosakun-2014" TOTAL_1="40" TOTAL_2="40" VAR="0.08025210084033613" WEIGHT="8.498641481101533"/>
<DICH_DATA CI_END="1.070938121367055" CI_START="0.7647918218176316" EFFECT_SIZE="0.9050108932461873" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="170" LOG_CI_END="0.029764378091243642" LOG_CI_START="-0.11645676476760554" LOG_EFFECT_SIZE="-0.04334619333818095" ORDER="33" O_E="0.0" SE="0.08589102312161856" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.0073772678528784144" WEIGHT="85.30234943856559"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5866146046123148" CI_END="1.2669657766623639" CI_START="0.668909010180055" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9205893892497493" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.10276488385942714" LOG_CI_START="-0.17463295407708074" LOG_EFFECT_SIZE="-0.03593403510882679" METHOD="MH" MODIFIED="2015-12-03 19:22:22 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6624287103276673" P_Q="1.0" P_Z="0.611603201542112" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="553" TOTAL_2="548" WEIGHT="100.0" Z="0.50778632707742">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7481195757668" CI_START="0.009379703419095869" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738134376766014" LOG_CI_START="-2.027810893549126" LOG_EFFECT_SIZE="-0.7269987279362623" MODIFIED="2010-06-22 15:06:15 -0400" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="2.3354166666666667" WEIGHT="3.7525611404158856"/>
<DICH_DATA CI_END="2.1842775109198698" CI_START="0.350516358920699" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3393078143462343" LOG_CI_START="-0.45529170830160776" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2015-12-03 18:58:19 -0500" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.4667516929344155" STUDY_ID="STD-Kiatchoosakun-2014" TOTAL_1="40" TOTAL_2="40" VAR="0.21785714285714286" WEIGHT="11.632939535289246"/>
<DICH_DATA CI_END="1.3262966797257771" CI_START="0.6308944995210203" EFFECT_SIZE="0.9147421931735658" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="51" LOG_CI_END="0.1226406824065224" LOG_CI_START="-0.20004325899135714" LOG_EFFECT_SIZE="-0.038701288292417375" MODIFIED="2010-06-22 14:53:48 -0400" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.18954614448838544" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.03592774089041189" WEIGHT="74.43567723091678"/>
<DICH_DATA CI_END="3.2778003013720998" CI_START="0.504320297913762" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5155824908287386" LOG_CI_START="-0.29729355197860247" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2010-06-22 15:29:01 -0400" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.47748741134633904" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.22799422799422797" WEIGHT="10.178822093378091"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.556844550612337" CI_END="1.0815972841189387" CI_START="0.8295388182928529" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9472206358271464" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="287" I2="20.601780811889068" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.03406558808938832" LOG_CI_START="-0.08116328634133463" LOG_EFFECT_SIZE="-0.023548849125973142" METHOD="MH" MODIFIED="2016-07-19 12:51:10 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.27239978994743663" P_Q="0.988203826704993" P_Z="0.42307405974689916" Q="2.1859177258977294E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="976" TOTAL_2="966" WEIGHT="200.0" Z="0.8010994881673311">
<NAME>Intraventricular haemorrhage</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.513208921577154" CI_END="1.0988235890418174" CI_START="0.8153764915647082" DF="2" EFFECT_SIZE="0.946548954297377" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="200" I2="63.723486114002306" ID="CMP-001.13.01" LOG_CI_END="0.0409279740837362" LOG_CI_START="-0.08864181401570194" LOG_EFFECT_SIZE="-0.023856919965982867" MODIFIED="2010-07-21 10:20:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06350708351554202" P_Z="0.47044623926845364" STUDIES="3" TAU2="0.0" TOTAL_1="458" TOTAL_2="449" WEIGHT="100.0" Z="0.721753189555208">
<NAME>Any intraventricular haemorrhage</NAME>
<DICH_DATA CI_END="2.7815628394166763" CI_START="0.9386540622566864" EFFECT_SIZE="1.6158357771260996" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.44428887571083464" LOG_CI_START="-0.027494435992260084" LOG_EFFECT_SIZE="0.2083972198592873" MODIFIED="2010-06-22 15:05:31 -0400" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.27712785265945505" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="0.07679984671964064" WEIGHT="5.628851353258608"/>
<DICH_DATA CI_END="1.2434708226070263" CI_START="0.23926629861185741" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.09463559923246896" LOG_CI_START="-0.6211184687816319" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2010-06-22 15:23:49 -0400" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.42043748259126085" STUDY_ID="STD-Ravishankar-2003" TOTAL_1="22" TOTAL_2="18" VAR="0.17676767676767677" WEIGHT="4.902547952838143"/>
<DICH_DATA CI_END="1.085684961886203" CI_START="0.7905180499300879" EFFECT_SIZE="0.9264197530864198" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="180" LOG_CI_END="0.035703822340092436" LOG_CI_START="-0.10208820935537581" LOG_EFFECT_SIZE="-0.033192193507641694" MODIFIED="2010-06-22 14:59:49 -0400" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.08093972149947544" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.006551238516412647" WEIGHT="89.46860069390324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0434086899154007" CI_END="1.2451612974895059" CI_START="0.7229234940902725" DF="3" EFFECT_SIZE="0.9487657012598478" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="87" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.09522561333720347" LOG_CI_START="-0.14090766100768154" LOG_EFFECT_SIZE="-0.02284102383523902" MODIFIED="2015-12-03 18:54:45 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5634461674713469" P_Z="0.7045600105036807" STUDIES="4" TAU2="0.0" TOTAL_1="518" TOTAL_2="517" WEIGHT="99.99999999999999" Z="0.37917217902720496">
<NAME>Severe intraventricular haemorrhage (Grade 3 or 4)</NAME>
<DICH_DATA CI_END="3.9346632651678948" CI_START="0.3475242089758317" EFFECT_SIZE="1.1693548387096775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5949075706627871" LOG_CI_START="-0.4590149365173074" LOG_EFFECT_SIZE="0.06794631707273985" MODIFIED="2010-06-22 15:05:51 -0400" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.6190792977181366" STUDY_ID="STD-Bental-1994" TOTAL_1="31" TOTAL_2="29" VAR="0.3832591768631813" WEIGHT="4.708369702160161"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2015-12-03 18:54:45 -0500" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Kiatchoosakun-2014" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="2.847804255338807"/>
<DICH_DATA CI_END="7.1754629737358115" CI_START="0.46437053363178427" EFFECT_SIZE="1.8253968253968254" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8558499277686766" LOG_CI_START="-0.33313534596861666" LOG_EFFECT_SIZE="0.26135729090002996" MODIFIED="2014-10-13 10:32:04 -0400" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.6984158353653123" STUDY_ID="STD-Mactier-2012" TOTAL_1="42" TOTAL_2="46" VAR="0.4877846790890269" WEIGHT="3.2620303288426338"/>
<DICH_DATA CI_END="1.2387710669849201" CI_START="0.6966385786561246" EFFECT_SIZE="0.9289648622981956" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="78" LOG_CI_END="0.09299105332380825" LOG_CI_START="-0.1569924787242542" LOG_EFFECT_SIZE="-0.032000712700222984" MODIFIED="2010-06-22 14:59:39 -0400" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.14684156416347266" STUDY_ID="STD-Tyson-1999" TOTAL_1="405" TOTAL_2="402" VAR="0.021562444965975258" WEIGHT="89.1817957136584"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-21 10:24:54 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="328" TOTAL_2="318" WEIGHT="0.0" Z="0.0">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2512924252474296" CI_START="0.4415306936612488" EFFECT_SIZE="0.7432926829268293" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.09735881555310655" LOG_CI_START="-0.35503910041173853" LOG_EFFECT_SIZE="-0.12884014242931596" MODIFIED="2010-06-22 14:55:20 -0400" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.2657407752435507" STUDY_ID="STD-Tyson-1999" TOTAL_1="328" TOTAL_2="318" VAR="0.07061815962704335" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.203455770181169" CI_END="1.0104347760636612" CI_START="0.6458766334499727" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8078466509708229" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="65" I2="42.34600749002717" I2_Q="57.81708061377079" ID="CMP-001.15" LOG_CI_END="0.004508284887582151" LOG_CI_START="-0.18985042709534314" LOG_EFFECT_SIZE="-0.0926710711038805" METHOD="MH" MODIFIED="2015-12-03 19:22:41 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.15749138990967426" P_Q="0.1236374942516244" P_Z="0.06161745245181854" Q="2.370627767234276" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="124" WEIGHT="100.0" Z="1.8690385413576214">
<NAME>Retinopathy of prematurity (any grade)</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6784155667831353" CI_END="0.9888572506430761" CI_START="0.4193230426540392" DF="2" EFFECT_SIZE="0.6439337163793821" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" I2="45.628764241310314" ID="CMP-001.15.01" LOG_CI_END="-0.004866397717830355" LOG_CI_START="-0.3774512715756068" LOG_EFFECT_SIZE="-0.19115883464671857" MODIFIED="2015-12-03 18:49:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15894337461243235" P_Z="0.04430825674712474" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="45.7873816854286" Z="2.0111628652817144">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="1.54069040743739" CI_START="0.1192150405435812" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18771537859539872" LOG_CI_START="-0.9236689491845875" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-12-03 18:49:52 -0500" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.6528326555791125" STUDY_ID="STD-Kiatchoosakun-2014" TOTAL_1="40" TOTAL_2="40" VAR="0.4261904761904761" WEIGHT="10.408822716397708"/>
<DICH_DATA CI_END="1.604854959796577" CI_START="0.5825929086873732" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.20543578876188093" LOG_CI_START="-0.23463480590245778" LOG_EFFECT_SIZE="-0.014599508570288439" ORDER="29" O_E="0.0" SE="0.2584996456904087" STUDY_ID="STD-Pearson-1992" TOTAL_1="22" TOTAL_2="18" VAR="0.06682206682206683" WEIGHT="17.992393552630322"/>
<DICH_DATA CI_END="1.0090267122421235" CI_START="0.19064597575432152" EFFECT_SIZE="0.43859649122807015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.00390266358655787" LOG_CI_START="-0.7197723575874655" LOG_EFFECT_SIZE="-0.3579348470004538" ORDER="30" O_E="0.0" SE="0.4250902896867499" STUDY_ID="STD-Shenai-1987" TOTAL_1="19" TOTAL_2="20" VAR="0.18070175438596492" WEIGHT="17.386165416400566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.52414205764695E-31" CI_END="1.1992475552513424" CI_START="0.7466820750562643" DF="0" EFFECT_SIZE="0.9462857142857142" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" I2="100.0" ID="CMP-001.15.02" LOG_CI_END="0.07890884179965345" LOG_CI_START="-0.12686427427451974" LOG_EFFECT_SIZE="-0.023977716237433153" MODIFIED="2010-07-21 10:22:40 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.6478366019626688" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="46" WEIGHT="54.2126183145714" Z="0.456769680641374">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="1.1992475552513424" CI_START="0.7466820750562644" EFFECT_SIZE="0.9462857142857143" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.07890884179965345" LOG_CI_START="-0.12686427427451968" LOG_EFFECT_SIZE="-0.0239777162374331" ORDER="31" O_E="0.0" SE="0.12087214697532153" STUDY_ID="STD-Wardle-2001" TOTAL_1="50" TOTAL_2="46" VAR="0.014610075914423731" WEIGHT="54.2126183145714"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4676225881691968" CI_END="2.943673908433664" CI_START="0.5478969744869953" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2699724517906334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.468889698460408" LOG_CI_START="-0.2613010977533369" LOG_EFFECT_SIZE="0.10379430035353557" METHOD="MH" MODIFIED="2014-12-30 11:09:39 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.49408296155466147" P_Q="0.49410223580462453" P_Z="0.5773871721725978" Q="0.4675808489490881" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="120" WEIGHT="100.0" Z="0.5572052990761412">
<NAME>Retinopathy of prematurity requiring laser therapy</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.189544960219487" CI_START="0.4696818655844824" DF="0" EFFECT_SIZE="1.8376068376068375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.856701403940671" LOG_CI_START="-0.3281962076017837" LOG_EFFECT_SIZE="0.2642525981694437" MODIFIED="2014-10-13 10:37:29 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38200307891593543" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="32.231404958677686" Z="0.8742115271192569">
<NAME>Supplementation via intramuscular injection</NAME>
<DICH_DATA CI_END="7.189544960219487" CI_START="0.4696818655844824" EFFECT_SIZE="1.8376068376068375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.856701403940671" LOG_CI_START="-0.3281962076017837" LOG_EFFECT_SIZE="0.2642525981694437" MODIFIED="2014-10-13 10:37:29 -0400" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.6960147223578099" STUDY_ID="STD-Mactier-2012" TOTAL_1="39" TOTAL_2="43" VAR="0.4844364937388193" WEIGHT="32.231404958677686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9641903913783976" CI_START="0.33736024612608756" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.47190609514720444" LOG_CI_START="-0.47190609514720444" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-13 10:38:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="67.76859504132231" Z="0.0">
<NAME>Supplementation via oral route</NAME>
<DICH_DATA CI_END="2.9641903913783976" CI_START="0.33736024612608756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47190609514720444" LOG_CI_START="-0.47190609514720444" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-13 10:38:37 -0400" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.5543999525246258" STUDY_ID="STD-Wardle-2001" TOTAL_1="77" TOTAL_2="77" VAR="0.30735930735930733" WEIGHT="67.76859504132231"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-11-14 06:56:29 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Vitamin A regimens: higher dose (10,000 IU) versus standard dose (5000 IU); both intramuscular and 3 x week for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:17:55 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death before 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.615876633570392" CI_START="0.3273304464252403" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20840820086629064" LOG_CI_START="-0.4850135971988535" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="40" O_E="0.0" SE="0.4073193966767246" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.16590909090909092" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen use at 36 weeks' postmenstrual age in survivors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.082280656173205" CI_START="0.8138486182406119" EFFECT_SIZE="2.71875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9581949181269456" LOG_CI_START="-0.08945636952952035" LOG_EFFECT_SIZE="0.4343692742987125" ORDER="41" O_E="0.0" SE="0.6153955523269199" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="32" TOTAL_2="29" VAR="0.37871168582375475" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:06 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.13" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death or oxygen use at 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.115709729958969" CI_START="0.6969244292065352" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.3254560833421525" LOG_CI_START="-0.1568143119420807" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="42" O_E="0.0" SE="0.28328801746691673" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.08025210084033613" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-07-22 04:18:06 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Retinol concentration on study day 28 (&#956;g/L)</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7788103484032534" CI_START="-0.2828569779704855" EFFECT_SIZE="0.24797668521638394" ESTIMABLE="YES" MEAN_1="350.0" MEAN_2="300.0" ORDER="38" SD_1="230.0" SD_2="160.0" SE="0.27083847834655006" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:04 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Retinol &lt; 200 &#956;g/L on day 28 (%)</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.14509943024982" CI_START="0.31847141598390405" EFFECT_SIZE="0.826530612244898" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3314474275268145" LOG_CI_START="-0.49692954115450466" LOG_EFFECT_SIZE="-0.0827410568138451" ORDER="39" O_E="0.0" SE="0.4865927319355344" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="28" TOTAL_2="27" VAR="0.2367724867724868" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-06-15 11:04:32 -0400" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Higher dos</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.755362190128103" CI_START="0.14803055289342476" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.829648638769922" LOG_CI_START="-0.829648638769922" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-22 14:45:28 -0400" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.95" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:14 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity (any grade)</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1268943858208067" CI_START="0.48343889840400295" EFFECT_SIZE="0.7380952380952381" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.05188321524348108" LOG_CI_START="-0.3156584083707366" LOG_EFFECT_SIZE="-0.13188759656362775" ORDER="43" O_E="0.0" SE="0.21589576907137062" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="32" TOTAL_2="31" VAR="0.046610983102918585" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:16 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="209.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity (threshold disease)</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5299914721713983" CI_START="0.005079227862196439" EFFECT_SIZE="0.0881542699724518" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.18468901016451003" LOG_CI_START="-2.2942023035969235" LOG_EFFECT_SIZE="-1.0547566467162066" ORDER="44" O_E="0.0" SE="1.4561130284133685" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="32" TOTAL_2="31" VAR="2.1202651515151514" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-08-02 04:18:59 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Sepsis (&#8805; 1 episodes)</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.12977251374821" CI_START="0.5237478953778437" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.052991004572118756" LOG_CI_START="-0.28087770918579225" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2010-06-22 14:45:03 -0400" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.19611613513818402" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03846153846153846" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-11-14 06:56:48 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Vitamin A regimens: once-a-week (15,000 IU) versus standard dose (5000 IU 3 x week); both intramuscular and for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death before 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.615876633570392" CI_START="0.3273304464252403" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20840820086629064" LOG_CI_START="-0.4850135971988535" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="47" O_E="0.0" SE="0.4073193966767246" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.16590909090909092" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen use at 36 weeks' postmenstrual age in survivors</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.594941483717761" CI_START="0.49813273675145053" EFFECT_SIZE="1.8125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8192109464462625" LOG_CI_START="-0.30265491596019983" LOG_EFFECT_SIZE="0.2582780152430313" ORDER="48" O_E="0.0" SE="0.6589895609031378" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="32" TOTAL_2="29" VAR="0.43426724137931033" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:39 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death or oxygen use at 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.817113834984233" CI_START="0.5503232547941482" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2593821349893349" LOG_CI_START="-0.25938213498933493" LOG_EFFECT_SIZE="0.0" ORDER="49" O_E="0.0" SE="0.304724700110022" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.09285714285714286" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2010-08-02 04:21:13 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="23" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Retinol concentration on study day 28 (&#956;g/L)</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.37506123874350195" CI_START="-1.5551226584867655" EFFECT_SIZE="-0.9650919486151337" ESTIMABLE="YES" MEAN_1="170.0" MEAN_2="300.0" ORDER="45" SD_1="90.0" SD_2="160.0" SE="0.3010416081753127" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="23" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-08-02 04:21:13 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="23" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Retinol &lt; 200 &#956;g/L on day 28 (%)</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.085827561972319" CI_START="1.2442185252422608" EFFECT_SIZE="2.515527950310559" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.7063616310749528" LOG_CI_START="0.09489666329068489" LOG_EFFECT_SIZE="0.4006291471828189" ORDER="46" O_E="0.0" SE="0.3591775488768852" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="23" TOTAL_2="27" VAR="0.12900851161720725" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-06-15 11:04:43 -0400" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.500739760948548" CI_START="0.26468284681954973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.57727420291097" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-06-22 14:48:59 -0400" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:46 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.57" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity (any grade)</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9978394316003459" CI_START="0.3930540973153761" EFFECT_SIZE="0.6262626262626263" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="-9.393380516018953E-4" LOG_CI_START="-0.4055476721469901" LOG_EFFECT_SIZE="-0.203243505099296" ORDER="50" O_E="0.0" SE="0.23766893829118627" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="33" TOTAL_2="31" VAR="0.056486524228459706" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:47 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity (threshold disease)</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1628808366666994" CI_START="0.1468809307603009" EFFECT_SIZE="0.5636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.33503259276146685" LOG_CI_START="-0.8330345840814092" LOG_EFFECT_SIZE="-0.2490009956599712" ORDER="51" O_E="0.0" SE="0.686128441703282" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="33" TOTAL_2="31" VAR="0.47077223851417405" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-22 04:18:48 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>One or more episodes of sepsis</NAME>
<GROUP_LABEL_1>Once-a-week dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once-a-week dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.179139659711921" CI_START="0.9574511407691243" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.33828506480273524" LOG_CI_START="-0.018883379067711422" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2010-06-22 14:48:38 -0400" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.20980251194181165" STUDY_ID="STD-Ambalavanan-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04401709401709402" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-08-16 10:01:44 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-08-16 10:01:44 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: review update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAN9CAYAAAAHQxhtAABwvElEQVR42uz9D4RX+f///7/JSrLW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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-08-16 10:01:44 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUAAAAJkCAIAAADvJ29AAAAf1klEQVR42u3dwW7UyNfG4ZaQEIss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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-08-16 10:01:39 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Supplemental vitamin A versus no supplementation, outcome: 1.1 Death (before 1 month).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvMAAAGQCAMAAAAUUx+MAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-08-16 10:01:34 -0400" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Supplemental vitamin A versus no supplementation, outcome: 1.2 Chronic lung disease (oxygen use at 28 days in survivors).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvMAAAIACAMAAAA43RNSAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-08-16 10:01:29 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Supplemental vitamin A versus no supplementation, outcome: 1.3 Death or chronic lung disease (oxygen use at 28 days).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvMAAAGQCAMAAAAUUx+MAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-08-16 10:01:21 -0400" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Supplemental vitamin A versus no supplementation, outcome: 1.4 Death before 36 weeks' postmenstrual age.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAAFwCAMAAAAymxUvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-08-16 10:01:16 -0400" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Supplemental vitamin A versus no supplementation, outcome: 1.5 Chronic lung disease (oxygen use at 36 weeks' postmenstrual age in survivors).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvMAAAGACAMAAAAXhR0XAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-11 12:34:46 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-07-11 12:34:46 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-07-31 14:28:19 -0400" MODIFIED_BY="[Empty name]">Standard search methodology</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-11 12:34:46 -0400" MODIFIED_BY="[Empty name]">
<P>PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))</P>
<P>Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or randomly or trial or clinical trial)</P>
<P>CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)</P>
<P>Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-07-31 14:29:03 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-07-21 05:50:55 -0400" MODIFIED_BY="[Empty name]">Data extraction fields for interventions and outcomes</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-14 06:58:45 -0500" MODIFIED_BY="[Empty name]">
<P>The authors collected the following data from each included trial.</P>
<UL>
<LI>General information</LI>
</UL>
<UL>
<UL>
<LI>Supplementation dose</LI>
<LI>Supplementation frequency</LI>
<LI>Time of initiation of supplementation</LI>
<LI>Vitamin A intake of control groups</LI>
<LI>Pre-randomisation vitamin A concentrations of supplemented and control groups (if available)</LI>
<LI>Post-randomisation vitamin A concentrations</LI>
</UL>
</UL>
<UL>
<LI>Number of the following outcomes in the supplemented and control groups</LI>
</UL>
<UL>
<UL>
<LI>Deaths</LI>
<LI>Reported as having a significant patent ductus arteriosus at 2 weeks of age</LI>
<LI>Developing neonatal chronic lung disease in the supplemented and control groups</LI>
<LI>Patent ductus arteriosus</LI>
<LI>Necrotising enterocolitis</LI>
<LI>Intraventricular haemorrhage</LI>
<LI>Periventricular leukomalacia</LI>
<LI>Retinopathy of prematurity</LI>
<LI>&#8805; 1 episodes of defined sepsis</LI>
<LI>Long-term neurodevelopmental disability</LI>
</UL>
</UL>
<UL>
<LI>Mean, standard deviation, and range of the following outcomes in the supplemented and control groups</LI>
</UL>
<UL>
<UL>
<LI>Gestational age</LI>
<LI>Birth weight</LI>
</UL>
</UL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;11 studies included in quantitative synthesis (meta-analysis)&lt;/span&gt;&lt;br&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="125">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 NEW studies included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;679 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;679 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;679 records identified through database searching (2011-2016)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;672 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;span&gt;3 full-text articles excluded, 1 classified as awaiting and 1 classified as ongoing, with reasons&lt;/span&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>